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�C Degree Celsius 
2-D Two-dimensional 
2-DE Two-dimensional gel electrophoresis 
A431/P Human squamous carcinoma cells 
A431/A10A DOX-resistant cells derived from A431 cells treated with stepwise 
acute, increase [DOX] from 5 // g/ml to 10 ji g/ml 
A431/CP500N CDDP-resistant cells derived from A431 cells treated with 
stepwise acute, increase [CDDP] from 100 // g/ml to 500 ji g/ml 
Apoptosis Programmed Cell Death 
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Bax Bcl-2 associated X protein 
Bcl-2 B-cell leukemia/lymphoma-2 gene 
BCP 1 -bromo-3 -chloropropane 
BLAST Basic local alignment search tool from Genbank, NCBI 
bp Base pair 
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cDNA Complementary Deoxy-ribonucleic acid 
CON Concanamycin A 
CP Cisplatin 
DD Differential display 
DEPC Diethyl pyrocarbonate 
DMEM Dulbecco modified Eagle's medium 
DNA Deoxyribonucleic acid 
DOX Doxorubicin 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
EtOH Ethanol 
FBS Fetal bovine serum 
GST- 71 Glutathione- S-transferase- n 
h hour 
Hepes/HEPES N-[2-hydroxyethyl]piperazine-N,-[2-ethanesylfonic acid] 
kDa kilodalton 
M Molar 
MALDI-TOF Matrix-assisted laser desorption ionization Time-of-Flight 
MDR Multidmg-resistance 
mg milli-gram (10-3 gram) 
ml milli-liter (lO'^  liter) 
mM milli-molar ( 1 m o l a r ) 
mRNA messenger RNA 
MRP Multidrug resistance-associated protein 
MTT 3-[4,5-Dimethylthiazol-2-yl-]-2,5-diphenyltetrezolium bromide 
MW Molecular weight 
ng nanogram (10'^  gram) 
nm nano-meter (10"^  meter) 
PBS Phosphate buffer saline 
III 
PBS-T Phosphate buffer saline with Tween 20 
PGR Polymerase chain reaction 
Pgp P-glycoprotein 
pi Isoelectric point 
PMSF Phenylmethysulfonylfluorid 
RNA Ribo-deoxy-nucleic acid 
RNAase A Ribonuclease A 
Rpm revolution per minute 
RT-PCR Reverse transcription-polymerase chain reaction 
SDS Sodium dodecyl sulfate 
TE Tris-EDTA 
TEMED N,N,N',N'-tetramethylethyethyenediamine 
jl g micro-gram (10"^  gram) 
ji 1 micro-liter ( 1 l i t e r ) 
ji M micro -mo lar ( 1 m o lar) 
UV Ultraviolet 




Drug resistance is one of the major obstacles in cancer chemotherapy. The cell model used 
for the experiment is human squamous carcinoma A431 cells and its drug resistant 
sublines, doxorubicin (DOX)-resistant AlOA and cisplatin (CP)-resistant CP500N cells. 
The drug-resistant cells were less sensitive to DOX- and CP-induced apoptosis and 
cytotoxicity. The underlying drug resistance mechanisms in A431 cells were investigated 
by studying the gene and protein expression profiles among different sublines. The 
approaches employed included cDNA microarray, reverse-transcription polymerase-chain 
reaction (RT-PCR) based differential display and 2-dimensional gel electrophoresis. 
Two-dimensional gel electrophoresis was employed to study the protein expression 
profiles among A431 cells. When comparing the proteomes between parent and drug-
resistant cells, 13 of the differentially expressed proteins were identified by matrix-
assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS). 
Western blotting was used to confirm the expressions of some of the proteins, e.g. MCM5 
and protein kinase c epsilon. Further investigation and characterization on the roles of the 
proteins identified are sought to be done. 
On the human cDNA microarray (ResGen™ GeneFilters�)，68 of the known genes were 
found to be overexpressed in the A431 parent cells, e.g. tumor susceptibility gene 101, 
gamma synuclein and 17 were overexpressed in the AlOA or CP500N cells, e.g. guanine 
nucleotide-binding protein, Sarcospan (kras oncogene-associated protein). By RT-PCR 
based mRNA differential display, which is a powerful method in gene expression profiling, 
5 ge^ies, both novel and known, with differential expression in A431 cells were identified 
and verified by Northern blot analysis. Two of the differentially expressed genes, V-
V 
ATPase subunit c and novel PA-8P19, were chosen for further characterizing for their role 
in drug resistance in A431 cells. 
By RT-PCR based differential display, a clone that had sequence homology to part of the 
sequence of vacuolar proton pump (V-ATPase) subunit c gene was found to be 
upregulated in CP500N cells. One of the functions of V-ATPase is for the regulation of 
cytoplasmic pH (pHi) and the increase in V-ATPase activity will lead to increased pHi. 
Using flow cytometric analysis, pHi in CP500N cells was more alkaline than that in A431 
parent and AlOA cells. Results from DNA fragmentation and MTT assay supported that 
the inhibitors of V-ATPases, bafilomycin A1 (BAF) and concanamycin A (CON), 
enhanced the CP-induced apoptotic cell death and cytotoxicity in A431 cells, while the 
inhibitors had no effect on DOX induced apoptosis and cytotoxicity. Decrease in pHi was 
found when cells were incubated in combined treatment of CP and BAF indicating that 
such changes may lead to V-ATPase inhibitor enhancement of CP induced apoptosis. 
The approaches of gene and protein expression profiling enabled the exploration of the 
underlying mechanisms of drug resistance in ceils. In-depth investigation is needed in 
exploring drug resistance mechanisms so as to improve the drug efficacy or modulate drug 

















來鑒定身份。其中2種MCM5及PKC £巳利用西方墨點方法（Western blotting)證實 
有不同表現。這些蛋白對藥物敏感度的角色會作進一步調查及硏究。 
於人體基因微陣列（ResGen™ Genefilters®)中，68種及口種巳知基因分別於A43l 
母細胞及其抗藥細胞有較明顯的表現。例如，腫瘤易感基因101 (tumor susceptibility 
gene 101)和G蛋白（guanine nucleotide-binding protein)分別方姆細胞及其抗藥細胞 
有較明顯的表現。而以RT-PCR爲本的微分顯示方法，是較有效率的基因表達分析 
技術;5種基因巳透過北方墨點方法(Northern blotting)被鑒定爲有不同表現，當中包 
括巳知及未知功能基因。其中2種有不同表現的克隆分別是vacuolar proton pump 
(V-ATPase) subunit c和未知克隆PA-8P19會被選用作爲硏究其抗藥性基制內的角 
色。 





細胞毒性(MTT assay)測試偵測到A431癌細胞內V-ATPase抑制劑bafilomycin A1 
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1.1. Review: Cellular Mechanisms of drug resistance in cancer 
cells 
Drug resistance is one of the major problems encountered during the treatment of 
many types of human tumors in chemotherapy. This phenomenon is extensively 
studied in the laboratory by using cultured cell lines as model systems (Hayes et al, 
1990, Borst, 1991, Pastan et al., 1991, McClean et al., 1992, Nielsen et al., 1992). Drug 
resistance is detected in cells after prolonged treatment of drugs or usage of combined 
drugs. The resistance can protect the cells, which are initially responsive to the 
anticancer drugs, against numerous drugs differing in chemical structure and 
mechanisms. Recent studies show that the molecular mechanisms of drug resistance 
are numerous. The resistance may be mediated by mechanisms operating at different 
steps of the cytotoxic action of the drug from decrease of drug accumulation in cells to 
the abrogation of apoptosis induced by chemical substance (Stavrovakaya, 2000). In 
this chapter, several classical multidrug resistance mechanisms will be discussed, 
1.1.1. Drug resistance by decrease of drug accumulation 
Many reports revealed that the occurrence of drug resistance might be derived from the 
decrease in anticancer drugs accumulation. One of the most investigated mechanisms 
2 
was the overexpression of P-glycoprotein (Pgp) in drug-resistant cells. Pgp is a large 
transmembrane glycoprotein with molecular weight approximately 170kDa and has 
two ATP-binding domains showing that Pgp function is energy-dependent. It 
comprises a subset of family proteins within the superfamily of ATP Binding Cassette 
(ABC) transmembrane transporters. Pgp is encoded by one of the isoform mdr gene, 
mdrl. Drug efflux from cells is mediated by the activity of transporter proteins such as 
Pgp. It was found that Pgp would increase the efflux of cytotoxic chemotherapeutic 
drugs and hence reduce the accumulation of drugs in cell (Bradley et al., 1988, Beck, 
1990, Gottesman et al , 1993, Zaman et al, 1994, Shustik et al” 1995，Deeley et al., 
1997, Tsumo et al , 2003). Some studies suggested that Pgp may function as flipase 
which moves bound substances to external membrane layer or outside the cell (Higgins 
et al., 1997). Also, it was suggested that the multidrug resistance (MDR) phenotype is 
usually associated with the elevated expression of only mdrl gene (Bookman, 1998). 
This phenomenon plays an important role in conferring multidrug resistance in tumor 
cells. Besides, the importance ofPgp-MDR for the outcome of tumor treatment can be 
shown in the clinical practice of multiple myeloma. In diagnosis, 6% of patients are 
found to be Pgp-positive. After combined therapy, up to 85% patients who are 
refractory to treatment become Pgp-positive (Marie et al., 1996). The clinical 
3 
significance of Pgp caught the attention of researchers to examine the ways to inhibit 
Pgp activity. Compounds such as calcium channel blockers, hypotensive drugs and 
immunosuppressors can partially restore the sensitivity of drug-resistant cells 
(Stavrovakaya, 2000). 
Recently, another drug effluxing pump, 190kDa multidrug resistance-associated 
protein (MRP), was discovered in 1992 (Loe et al, 1996), the protein belongs to the 
family of ABC transporter. Elevated expression of MRP was detected in numerous 
non-Pgp multidrug resistant cells including cervival, breast, small and non small cell 
lung cancer (Fan et al, 1995). Recent studies suggested that overexpression of MRP is 
involved in decreased cisplatin accumulation and increased vincristine efflux in 
cisplatin-resistant epidermoid carcinoma cells (Asada et al., 1998) and murine 
doxombicin-resistant cells (Slapak et al., 1996) respectively. This protein contributes 
to the resistance to almost the same antitumor drugs as Pgp and such resistance can be 
reversed by verpamil (Binaschi et al., 1995), nonimmunosuppressive cyclosporin A 
analogue and the carboxamide derivative (Sikic, 1997, Sandor et al, 1998). Although 
the clinical significance of MRP is not yet clear, there are data suggesting that MRP 
may cause MDR in drug-resistant cells. 
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1.1.2. Drug resistance conferred by detoxiflcation of drug in cells 
Another drug resistance mechanism is mediated by detoxification of drug in cells. The 
cellular glutathione (GSH) system is a critical component of detoxification of cytotoxic 
anticancer drugs in cells. Glutathione, a non-protein thiol, can interact via its thiol with 
the reactive site of a drug, resulting in conjugation of drug with glutathione. The 
conjugate is less active, more water-soluble, and is excluded from the cells with the 
participation of transporter proteins named GS-X (including MRP). Elevated levels of 
glutathione were found in cell lines resistant to alkylating agent such as BCNU (Tew, 
1994). The enzymes glutathione S-transferases (GST) catalyze the interactions 
between glutathione and alkylating drugs, increasing the rate of a drug detoxification. 
Therefore, activation of these enzymes can cause cellular drug resistance (Tew, 1994, 
Hayes et al , 1995, Zhang et al., 1998, Harbottle et al., 2001, Bemardini et al., 2002). 
Resistance of tumor cells to drugs of Pgp-MDR group can also be connected with 
alterations of the GSH system (Sinha et al., 1989, Cao et al., 1999, Liu et al., 2001). In 
cells with Pgp-MDR, increased levels of a G S T isoenzyme, GSTTC, is frequently found 
and developed the drug resistance to anticancer agents such as doxorubicin, cisplatin 
etc (Hickson et al., 1997, Goto et al., 2001, 2002). Also, transfection of human GSTs 
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gene into the Saccharomyces cerevisiae conferred significant levels of resistance to 
doxorubicin (Black et aL, 1990). 
1.1.3. Drug resistance conferred by alterations of drug targets or by 
enhancement of target repair 
DNA topoisomerase is one of the proteins involved in drug resistance mechanisms in 
cells. It can be divided at least into two types: I and II. Topoisomerase I is a lOOkDa 
nuclear enzyme implicated in many aspects of DNA metabolism, including replication 
and transcription (Wang, 1985, Garg et al., 1987, Yanagida et aL, 1987, Liu et al., 
1989). It can alter the pitch of double helices by cutting one DNA strand and allowing 
the passage of complementary strand through the transient nick (Kay et al, 1997). 
There are two different types of topoisomerase II a and /5 of which only the a form 
is believed to contribute to drug resistance in cells. Topoisomerase II a is a 
homodimer with a subunit ITOkDa which mediates the transient breakage of both 
strands of a DNA molecule and passage of an intact duplex through this break. Thus, 
topoisomerase II a can catalyze not only the relaxation of supercoil DNA, but also 
formation and resolution of interlinked rings of double stranded DNA; these reactions 
are termed catenation and decatenation. Generally, it may stated that the more 
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topoisomerase II a activity there is within the cell, the more sensitive the cell will be 
to topoisomerase II inhibitors as a higher level of enzyme will result in DNA lesions. 
This has been confirmed in a few studies of tumor cell lines where enzyme activity and 
chemo sensitivity were inversely correlated. Topoisomerase I is the intracellular target 
for camptothecin and its analogue (Hsiang et al , 1985) while topoisomerase 11 
inhibitors are doxorubicin, mitoxantrone and etoposide (Liu, 1989). These drugs 
stabilize the DNA-topoisomerase complex which in normal circumstances is easily 
decomposed. However, changes in the activity by genomic alterations or decreased 
transcription of topoisomerases gene results in the resistance to anticancer drugs in 
drug-resistant cells. The point mutation in the topoisomerase I gene significantly 
reduced the activity and is associated with camptothecin resistance in camptothecin 
resistant lung, nasopharyngeal carcinoma and leukemia (Eng et al., 1990, Kubota et al., 
1992, Chang et al., 2002, Urasaki et al., 2000). Besides, reduced activity and 
insensitivity of topoisomerase II inhibitors were found in resistant cells and contribute 
to camptothecin, doxorubicin, cisplatin and etoposide resistance in pancreatic, renal 
and ovarian carcinoma (Kikuchi et al., 1997, Schelterm et al., 1997, Okada et al., 2001, 
Lage et al.，2002). 
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Another way of drug target alteration is an increase in the quantity of target protein in 
cells. For example, increased levels of dihydrofolate reductase (DHFR) were found to 
be resistant to methotrexate (MTX) in MTX-resistant cell lines (Guo et al” 1999). This 
increase was due to the amplification or mutation of DHFR gene (Denis et al., 1991, 
Bertino et al., 1996). 
Enhanced DNA damage repair is implicated in drug resistance to the drugs that 
interacting with DNA. There are several repair mechanisms in human to protect the 
genome by damage reversal, base excision, nucleotide excision, post-replication and 
mismatch repair (Cml et al., 1997). Changes in the quantities of proteins that 
recognizing and repairing DNA injuries, such as ERCCl, ERCC2, BRACl, were 
found in cultured cells with altered sensitivity to platinum complexes (Chu, 1994). For 
instance, a 2.6-fold expression of ERCCl gene was found in patients resistant to tumor 
therapy (Dabholkar et al., 1992). Also, upregulation of BRACl is associated with 
repair-mediated resistance to cis-diammmedichloroplatinum(II) (Husain et al, 1998). 
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1.1.4. Drug resistance conferred by genes alteration in apoptotic 
pathways 
The gene p53 and the genes regulated by p53 are critical components of the cell 
response to stresses, including cell reactions upon the influence of antitumor drugs 
(Chumakov, 2000, Kopnin, 2000). Normal p53 is activated in response to cell injuries 
and its alterations result in cell cycle arrest or programmed cell death/apoptosis. 
However, alteration of p53 and impaired balance of apoptosis-related proteins may 
lead to blockage of cell death or progress in cell cycle checkpoint after damage. Thus, 
alterations of these genes and proteins result in changes in tumor cell sensitivity to the 
drugs, in particular, in multidrug resistance. Mutation or loss of p53 function is 
frequent in tumors that confer the drug resistance in many cells (EHedge et al., 1995, 
Keshelava et al, 2001). Also, the proteins whose synthesis are controlled by the 
transcriptional regulator p53 (e.g. MDM) can influence cell sensitivity to the 
drugs. Bcl-2 family is also an important component in regulation of apoptosis in cells. 
Therefore, altered expressions of anti-apoptotic and pro-apoptotic effectors result in 
impaired balance of cell survival. This phenomenon was found in the cells that showed 
chemoresistance. The Bcl-2 proteins are involved in the control of apoptosis in 
different cell types and function as either inhibitors (Bcl-2, BC1-XL, MC1-1 and Al) or 
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promoters (Bax, Bad, Bal，Bcl-Xs) of cell death (Adams et al., 1998). It was suggested 
that resistance to several anticancer drugs was due to the overexpression of Bcl-2 and 
BCI-XL and reduced expression of Bax (Miyashita et al, 1994, Dive, 1997, Nuessler et 
a l , 1999, Konopleva et al, 2002, Shi et al., 2002). Besides, there are data 
demonstrating the involvement of CD95-L/CD95 (FasLigand/Fas) in drug-induced 
death of cancer ceils and suggesting a contributory role of the alterations of the 
function of this system in the occurrence of drug resistance (Herr et al., 1999). It was 
shown that lymphocytes of mice with the mutation in the gene encoding CD-95 
receptor and ceil lines resistant to CD95-L are resistant to a number of 
chemotherapeutic drugs (Friezen et al, 1996, Landowski et al, 1997, Reap et al., 
1997). 
Although different cellular drug resistance mechanisms are extensively studied for 
many years, the distinct directions or pathways for development of chemsoresistance 
are still under investigation and pursed. Contradiction and inconclusive results were 
shown in many different carcinoma cell lines. Other known or novel mechanisms 
correlated to chemoresistance were studied and investigated in recent years. 
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1.2. Objective and overview 
As the drug resistance mechanisms are diverse and multifactorial, drug-resistant, 
cisplatin (CP) and doxorubicin (DOX)-resistant, cell lines derived from human 
squamous carcinoma A431 cells were used as the cell model to investigate the new 
potential targets for modulating the drug sensitivity and hence elucidating the drug 
resistance mechanisms encountered in cancer chemotherapy. The DOX-resistant AlOA 
subline was derived from the human squamous carcinoma A431 cells that survived 
after acute high dosage of 5 ^g/ml followed by 10 |xg/ml doxorubicin (Kwok and 
Sutherland, 1991). The CP-resistant CP500N cells were derived in our laboratory from 
the A431 parent cells that survived after the stepwise concentration from 100|ig/ml, 
then 250|ig/ml and finally survived after 500|ag/ml cisplatin. Both AlOA and CP500N 
were more resistant to DOX and CP than their A431 parent cells. The DOX- and CP-
resistant sublines were cross-resistant to other chemotherapeutic drugs such as cisplatin, 
doxorubicin, etoposide, methotrexate and camptothecin. In the present studies, the drug 
resistance was not correlated to the altered expression of the typical multidrug 
resistance factors, such as Pgp, GST-pi and MRP, as their expressions were similar 
among the cells (Figure 1.1). The studies demonstrated that other mechanisms might 
be responsible for the drug resistance in these cell lines. 
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Figure 1.1. Expression of the typical multidrug resistance proteins in human 
squamous carcinoma A431 ceils by Western blot analysis. The basal levels of P-
glycoprotein (Pgp), glutathione-S-transferase-pi (GST), multidrug-resistance 
associated protein (MRP) in various A431 cells were analyzed by Western blot. Protein 
were extracted from exponentially growing cells and resolved by SDS-PAGE and fater 
immunoblotted with the corresponding antibodies. Cell lines: P: A431/pareiit cells; 
A: A431/A10A cells; N: A431/CP500N cells 
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Chemotherapeutic drugs DOX and CP were used in the study. They are most widely 
used cytotoxic anticancer drugs in cancer chemotherapy. DOX is a natural product 
derived from fermentation of Streptomyces as discovered in 1968. It is a member of 
anthracyclines. The action mechanisms include free radical formation, intercalation 
into DNA with consequent inhibition of macromolecules biosynthesis and DNA 
damages (Gewitz, 1999). CP is an inorganic compound that was first synthesized in 
1844 and the tumor-inhibiting effects were discovered in 1969. The action mechanism 
is adduct formation results in inhibition of DNA replication, RNA transcription, G2 
phase arrest in cell cycle (Deborah et al., 1995). 
Although many common mechanisms of drug resistance were described in this chapter, 
inconclusive results were shown in different types of tumor cells. In order to further 
investigate the underlying mechanisms, two of the powerful tools，cDNA microarray 
and mRNA differential display, were employed to study the gene expression profile in 
A431 parent and drug-resistant cells as discussed in Chapter Two. Alteration of geae 
expression profile will help the identification of the potential targets associated with 
novel drug resistant mechanisms. Two of the differentially expressed genes from 
differential display were selected for further characterization for their role in drug 
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resistance. One of the cDNA clones, vacuolar proton pump (V-ATPase) subunit c, was 
identified to be upregulated in the drug-resistant cells and their association with drug 
sensitivity is to be discussed in Chapter Three. Moreover, a novel cDNA clone named 
PA-8P19 that underexpressed in DOX- and CP-resistant cells was selected for further 
characterization and the results were shown in Chapter Four. Besides, another 
approach, two-dimensional gel electrophoresis, was employed to study the protein 
expression profiles in A431 cells and the results were presented in Chapter Five. 
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CHAPTER TWO 
Profiling and Identification of Differentially 
Expressed Genes of 
Human Squamous Carcinoma A431 Cells by 
mRNA Differential Display and cDNA Microarray 
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2.1. INTRODUCTION 
2.1.1. Changes in Gene Expression and Drug resistance 
Drug resistance is one of the major obstacles for successful cancer chemotherapy. 
Several mechanisms of drug resistance in tumors are identified, such as overexpression 
of the P-glycoprotein, MRP, GST and increased DNA repair (Stavrovakaya, 2000) as 
discussed in Chapter One. The alterations of these genes may be due to either drug 
induction or drug selection during chemotherapy. Such alterations may result in escape 
of some cancer cells from killing and later on forming the relapsed resistant tumor. 
More likely, the occurrence of drug resistance in cells may involve the changes in 
multiple genes expression. Therefore, by studying the differential gene expressions in 
drug resistant and parent cells, the results may help us to better understand the 
molecular mechanisms and facilitate the identification of novel or known targets 
associated with drug resistance and hence develop more effective strategies for cancer 
treatment in foture. In order to monitor the global genomic expression profiles in a 
simple, sensitive and high throughput way, extensive technologies were developed to 
determine transcription patterns or to identify differentially regulated genes in cells. 
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2.1.2. Current state of technologies in gene expression analysis 
Of the estimated 40,000 to 50,000 genes embedded in our genome, only 10-15% of 
them are "turned on" (expressed as mRNAs for protein synthesis) at any given time in 
each of our cells. Thus, interpretation of the genomic instruction will have to rely on 
tools that can allow us to determine when and where a gene is to be turned on or off in 
a cell as it divides, differentiates and ages (Liang, 2002). By monitoring and comparing 
the differentially gene expression profile in different types of cells, a seemingly precise 
interpretation of biological process such as cancer can be reviewed. 
Different strategies for studying the differentially expressed genes including RNA-
arbitrarily primed PGR fingerprinting (RAP-PCR), serial analysis of gene expression 
(SAGE), DNA microarray, representational differences analysis (RDA), subtractive 
hybridization (SH) and differential display (DD) were invented. SH and cDNA 
microarray are based on the hybridization, while RAP-PCR and DD are based on PGR 
technology. SAGE relies on the technique of sequencing. Now, nearly 10 years after 
initial description of DD and DNA microarray methodology, the number of 
publications using these techniques has exploded to more than 1200, which are more 
than the other competitive methodologies. Other methodologies such as SH and SAGE 
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is also widely used in studying gene expression patterns. However, several technical 
difficulties and drawbacks were discovered. SH and SAGE are time consuming and 
labour intensive for constructing cDNA libraries and analyzing the gene expression. 
Moreover, a large amount of input RNA was necessary and the techniques were hardly 
performed on multiple samples comparison. Therefore, DD and microarray have 
rapidly become the better choice for investigating the differential gene expression in 
different systems in recent 10 years. In the present study, both methods were employed 
for studying the gene expression profiles among A431 cells. Table 2.1 shown the 
number of publications with different technologies for comparative gene expression 
study by Medline searches (Liang, 2002). 
2.1.3. Monitoring the gene expression profile in the field of drug 
resistance by cDNA microarray 
The rapid progress in human genome project results in the identification of almost all 
human genes and there will be a need for technology that can rapidly assess the 
expression level of genes in many different samples. One of the techniques, DNA 
microarray, has become a popular method for detecting changes in gene expression. 
Microarray methods were initially developed to study differential gene expression 
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using complex populations of RNA (Lipshutz et al., 1999). Refinements of these 
methods now permit the analysis of copy number imbalances and gene amplification of 
DNA (Pollack et al, 1999) and have recently been applied to the systematic analysis of 
expression at the protein level (Haab, 2001). Many of the guiding principles of global 
analysis using microarrays are applicable for the RNA, DNA or protein level. In this 
study, the attention was focused on microarray technologies applied to the analysis of 
RNA, with emphasis on the study of gene expression changes in drug resistance in 
cancer. Development of DNA microarrays opens a new direction for simultaneous 
interrogation of the expression of thousands of genes in a high-throughput fashion 
(DerRisi et al., 1996, 1997, Schena et al., 1996) and offers a new opportunity to obtain 
molecular signatures of the state of activity of diseased cells and patient samples. DNA 
microarray analysis may provide invaluable information on disease pathology, 
progression and resistance to drug treatment. Indeed, this technology has been widely 
used in the past 3 years for the investigation of tumor classification (Mariadason et al., 
2003, Sorlie et al, 2003, Zhang et al, 2003), cancer progression (Sgroi et al” 1999, 
Calvo et al, 2002, Zeng et al., 2002), and chemotherapy resistance and sensitivity 
(Kudoh et al., 2000, Keshelava et al., 2001, Sakamoto et al, 2001, Vikhanskaya et al., 
2001, Hoshida et al., 2002, Scheffer et al., 2002). 
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The idea of DNA array analysis is based on the techniques for analyzing gene 
expression such as Northern, Southern and dot blot analysis (Southern, 1975, Kafatos 
et al., 1979, Sambrook et al., 1989, Southern et al, 1999). DNA arrays can be 
classified according to their fabrication or DNA used. Two categories can be divided 
according to fabrication: High-density filter arrays (HDFAs) and microarray. The 
DNA was spotted on nylon and glass/silicon chips respectively. According to DNA 
used on the arrays, they can be classified into silicon-based DNA chips and cDNA 
arrays. Partial or foil length of cDNAs can be spotted robotically at high density onto 
glass slides or nylon membranes. About 10,000 cDNAs were allowed to spot on the 
slide and thus facilitated miniaturization and fluorescent dye detection (Schena et al., 
1995 and Celis et al, 2000). For gene chips or DNA chips, 20 to 30 base pairs 
oligonucleotides can be synthesized onto silicon chips by photolithography as 
developed by Affymetrix Inc. (Pease et al., 1994, Lipshutz et al, 1995, Cheung et al., 
1999, Lipshutz et al, 1999). Photolithography is well known in the computer chip 
industry and utilizes an ultraviolet light source that passes through a mask that directs 
in a step-wise manner where a photochemical reaction takes place on a siliconized 
glass surface. About 400, 000 distinct oligonucleotides can be fixed onto the chip. 
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In our laboratory, we use the ResGen^^ GeneFilters® mammalian cDNA microarrays 
manufactured by Invitrogen Corp. to study the differential gene expression pattern 
between human squamous carcinoma A431 parent and drug-resistant cells, AlOA and 
CP500N. ResGenTM GeneFilters® microarray was widely used in different fields 
(Bubendorfet al., 1999, Moch et al., 1999, Sgroi et al., 1999, Rep et al, 2000, Walker 
et al, 2000, Lee et al., 2001, McCormick et al, 2001). The protocol of microarray 
experiment was shown in Figure 2.1. mRNAs were extracted from exponentially 
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growing A431 cells and were reverse-transcribed and radiolabeled with [ P]dCTP. 
The radiolabeled cDNA were hybridized with membranes of human cDNA microarray 
in parallel at 42�C. The signals were detected by phosphor imaging and analyzed by 
Pathway 4 software. The technique of cDNA microarray analysis also provides a new 
trend in identifying mechanisms that related to drug resistance. The clone selection in 
microarray was based on the criteria that the clones: (a) contain the 3’ untranslated 
region; (b) are of average size ( � 1 kb); and (c) originated from oligo-dT primed 
libraries. These selected clones have been sequence verified at the sequencing facilities 
of Research Genetics. All of these clones are from the IMAGE libraries. After PGR 
amplification, 0.5 ng of insert cDNA was printed on a charged nylon membrane by a 
custom-made robot. Genes (n 二 5184) were spotted on a 5 x 7-cm nylon membrane. 
21 
Each membrane contains a system of controls including putative housekeeping gene 
(PHK) genes. It is divided into two fields. Each field is divided into eight grids. Grids 
are laid out right to left, A through H in each field. Columns are organized into 12 
columns and 30 rows. The PHK genes are in column 1, rows 13 through 24 (ResGen™ 
GeneFilters® technical manual from http://www.resgeii.CQm). For a list of genes 
spotted onto membrane, ResGen^^ ftp site can be found. 
Comparing gene expression profiles of parent cell with either AlOA or CP500N in 
cDNA microarrays, 85 genes were detected as differentially regulated respectively. 68 
genes were overexpressed in A431 parent, 17 genes were overexpressed in the drug-
resistant, AlOA and CP500N, cells. 
2.1.4. Monitoring the gene expression profile in the field of drug 
resistance by differential display 
Gene discovery, i.e. detection of genes of which the expression is affected in diseases 
or by different treatments of cells, has become the focus of many genetic researches. 
The technologies that are used to detect changes in gene expression level include 
polymerase chain reaction (PCR)-based subtractive cloning (Hubank et al” 1994, Cho 
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and Park, 1998), serial analysis of gene expression (Velculescu et al, 1995, Zhang et 
al , 1997), Northern blotting (Alwine et al.，1977) and RNase protection (Berk and 
Sharp, 1977). The above technologies all have limitations with respect to sensitivity, 
amount of material required, number of samples that can be compared, detection of 
both upregulated and downregulated genes or the cost per analyzed samples. An 
alternative method, excluding most of these limitations, PCR-based differential display 
(DD) was introduced in 1992 by Liang and Pardee (Liang and Pardee, 1992). Judging 
by the number of publications, DD has already become by far the most popular method 
for detecting changes in gene expression. The rapid and relatively simple technology is 
based on the assumption that practically all expressed mRNA can be reverse-
transcribed into cDNA and amplified by PGR provided that a sufficiently large number 
of primer combinations are used. Many RNA samples can be compared simultaneously 
by DD and both up and downregulated genes are detected. Moreover, only a small 
amount of total RNA is required, and it therefore allows a DD analysis to be carried 
out when a small amount of tissues is available. Now, nearly 10 years after the initial 
description of DD methodology, the number of publications describing the applications 
of DD has exploded to more than 3800 (Table 5.1), which outcomes the combined total 
of those using other competitive technologies. DD can be applied in the areas of 
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research including disease marker identification, growth and development, cancer 
research and pharmacological targets in drug discovery. Studying drug resistance 
mechanisms in cancer is one of the widely applied areas (Slovak et al, 1988, Feller et 
al , 2000, Wong et aL, 2000, Murakami et al., 2001, Yamamoto et al., 2001, Parekh et 
al., 2002). Since DD is capable of detecting both differentially expressed novel and 
known genes, so the method provides an alternative strategies in exploring any novel 
potential targets associated with drug resistance rather than the typical targets. For 
examples, a novel cisplatin resistance related gene 9 (CRR9) which was upregulated in 
CDDP-resistant ovarian tumor cell line was found to be associated with apoptosis 
using mRNA different display approach (Yamamoto et al., 2001). Using differential 
display approach, a novel mRNA that is downregulated in doxorubicin resistant human 
cell lines, was identified to be associated with drug-related toxicity (Fanciulli et al., 
1996). 
In the present study, A431 parent cells were analyzed in parallel with 2 drug-resistant 
sublines, AlOA and CP500N, for a comparative study of the gene expression profiles 
using mRNA differential display. The result of genes identified to have differential 
expression among these cells was presented in this chapter. Northern blot analysis was 
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employed to verify their expression. The protocol of DD was shown in Figure 2.2. 
Total RNA from exponentially growing A431 cells were extracted and DNA 
contamination was removed by treating the samples with DNase I. Three different one-
base-anchored oligo-dT primers were used to subdivide the pool of mRNA by binding 
to the poly-A tail in reverse transcription. These populations of cDNAs were amplified 
and radiolabeled by PCR with the use of different arbitrary primers provided in the 
RNAimage kit. The amplified cDNAs were resolved in 6% denaturing poly aery lamide 
gel electrophoresis and visualized by autoradiography. Bands that are unique or 
differentially expressed were extracted and reamplified by PCR and later subcioned 
and their expression patterns were verified by Northern blot analysis (Liang et al., 
1994, Vogeli-Lange et al., 1996) 
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Methods Year Invented Medline Hits 
DD 1992 3862 
Microarrays 1995 1196 
Substractive Hybridization 1985 886 
SAGE 1995 644 
RDA 1993 288 
Medlines searches conducted on January 14, 2002 by PubMed at the NCBI Web site. 
Table 2.1. Impact of Major Technologies in Gene Expression Analysis. 
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2.2. MATERIALS AND METHODS 
2.2.1. Materials 
Chemicals Company 
• 1 -bromo-3-chloropropane (BCP) Molecular Research Center, Inc. 
• 2X Trypsin with EDTA Invitrogen Corporation 
• 2-mercaptoethano 1 Sigma 
• Acrylamide/ bisacry larnide Bio-Rad 
• Agarose Invitrogen Corp. 
• Ammonium persulphate Sigma 
• Bromophenol blue Sigma 
• Calcium chloride Sigma 
• Cisplatin Sigma 
• Chloroform BDH Laboratory Suppliers 
• Diethyl pyrocarbonate (DEPC) USB 
• Dimethyl sulfoxide (DMSO) Sigma 
• Doxorubicin Sigma 
• Dulbecco's Modified Eagles’s medium 
(DMEM) Invitrogen Corp. 
• Ethanol BDH Laboratory Suppliers 
• Ethidium bromide Sigma 
• Ethylenediamietetraacetic acid (EDTA) USB 
• Fetal bovine serum Invitrogen Corp. 
• Formaldehyde Sigma 
• GeneFiltersd) Probe Labeling and Purfication 
Kit Invitrogen Corp. 
• Glycerol Sigma 
• Glycine Invitrogen Corp. 
• Isoamyl alcohol Sigma 
• Isopropanol BDH Laboratory Suppliers 
• L-glutamate Invitrogen Corp. 
• Magnesium chloride Sigma 
• MessageClean Kit GeneHunter Corp. 
• Metaphosphoric acid Sigma 
• Methanol BDH Laboratory Suppliers 
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• N,N,N，,N,-trtramethylethylenediamine 
(TEMED) Invitrogen Corp. 
• Phenylmethysulfonylfluorid (PMSF) Boehringer Mannheim 
• Phosphate buffer saline (PBS) Invitrogen Corp. 
• Plasmid mini-preparation kit Qiagen 
• QIAGEN mini-preparation kit Qiagen 
• QIAEXII gel extraction kit Qiagen 
• Redprime II random prime labeling system Amersham Biosciences 
• RNAimage mRNA differential display system GeneHunter Corp. 
• Sodium acetate Sigma 
• Sodium Dodecyl Sulfate (SDS) Invitrogen Corp. 
• Sodium diphosohate Sigma 
• Sodium orthovanadate Sigma 
• TRI reagent Molecular Research Center Inc. 
• Tris base USB 
• Urea Sigma 
Culture wares Company 
• 75cm^ culture flask Coming / Falcon 
• 60mm and 100mm culture dishes Coming / Falcon 
• 96-well flat-bottom culture plate Coming / Falcon 
• microftige tube MBP 
Instruments Company 
• Film cassette Kodak 
• Microplate reader Molecular Device 
• Pathways丁M 4 software ResGen, Invitrogen Corp. 
• Phosphor imaging system Packard Cyclone 
• Thermal cycler 9700 Perkin Elmer 
• Trans-Blot SD semi-transfer cell Bio-Rad 
• UV transilluminator UVP 
• X-rays film Fuji 
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2.2.2. Methods 
2 . 2 . 2 . 1 . Cell cul ture and ce l l l ines: 
Human squamous carcinoma A431 cells, and the doxombicin-resistant, AlOA (Kwok 
and Sutherland, 1991) and the cisplatin-resistant cell lines, CP500N were cultured in 
Dulbecco modified Eagle's medium supplemented with 10% fetal bovine serum and 
5mM L-glutamate in 37°C humidified 10% CO2 incubator. 
2 . 2 . 2 . 2 . cDNA microarray 
2 . 2 . 2 . 2 . 1 . RNA preparation 
Cells were lyzed with 1ml TRI reagent. The RNA was extracted by 0.1ml l-bromo-3-
chloropropane (BCP) reagent. The RNA in supernatant was collected and transferred 
to new microfbge tube after centrifligation at 12000g at 4�C for 15 min. 0.5ml 100% 
isopropanol was added with vigorously shaking and then stored for 10 min to allow the 
precipitation of RNA RNA pellet was collected after centrifligation at 12000g at 4�C 
for 7 min. After removal of isopropanol, the RNA pellet was air-dried at room 
� 
temperature for 15 min. RNA pellet was dissolved in 20ul DEPC-treated water at 55-
60�C for 10 min. RNA was aliquoted and store at _70�C until further analysis. 
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2 . 2 . 2 . 2 . 2 . Differential hybridizat ion of ResGen GeneFil ters 
Mammal ian microarray 
Differential gene expression of human squamous carcinoma A431 parent cells and its 
sublines, AlOA and CP500N cells, was investigated by hybridization of the mRNA 
samples from the cells with GeneFilters� mammalian microarrays membrane. The 
membrane was pretreated by boiling in 0.5% SDS and gently shaked for 10 min. The 
membrane was then pre-hybridized in 5ml MicroHyb buffer containing Poly dA and 
Cot-1 DNA at 42�C for at least 2 hr in a hybridization oven. cDNA probes were 
synthesized by incubating the mixture of 10//g RNA, oligo-dT and DEPC-treated 
water at 70�C for 10 min and kept on ice for 2 min. Then the following reagents 
including 5X RT buffer, 20mM dNTP mix, RNase inhibitor, AMV reverse 
transcriptase and a -[^^P]dCTP were added and incubated at 42�C for 2 h. The 
radiolabeled cDNA probe was loaded into pre-washed Simple Nucleic Acid 
Purification column (S.N.A.P.) and was recovered by loading TE buffer containing 
lOmM Tris-HCl and ImM EDTA into the column after centrifogation. The cDNA 
probe was denatured at 100�C for 3 min and kept on ice for 2 min and mixed with 
MicroHyb buffer. The radiolabeled cDNA probe was hybridized with the 
prehybridized membranes at 42�C for 12-18 h. The membrane was washed with SDS-
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containing water at 50°C for 20 min twice and then washed at 55�C for 15 min once. 
After stringent washes, the GeneFilters® images were visualized by exposure of 
membranes to phosphor imaging screen using Packard Cycione. The phosphor image 
data is imported into Pathways^'^ software for gene expression analysis. 
2 . 2 . 2 . 3 . mRNA differential display 
2 . 2 . 2 . 3 . 1 . RNA preparation 
The procedures of RNA preparation were the same as that described in section 2.2.2.2. 
The DNA contamination was removed with the MessageClean kit by the DNase I 
treatment. 
2 .2 .2 .3 .2 . RT-PCR based mRNA differential display 
The RNAimage kit was used and the schematic diagram was shown in Fig. 2.2. 0.1 
figl fi\ DNA-free RNA was reverse transcribed with MMLV reverse transcriptase, 20 
f iM dNTP and an anchored oligo-dT primer, H-TuA. Then, the first strand cDNA 
was amplified and radiolabeled with a second short arbitrary primer (2 different 
primers from RNAimage kit), 2 / /M dNTP, H-TnA and a -[^^S]dATP by 40 cycles of 
polymerase chain reaction (PGR). The PGR conditions were shown as follows: 94�C 
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for 30 sec, 40°C for 2 min, 72°C for 30 sec and followed by 72�C for 5 min. RT-PCR 
products from A431 parent cell and its sublines were run in parallel in 6% denaturing 
polyacrylamide gel. The gel was blotted onto 3M paper and dried under vacuum at 80 
�C for 1 hr. The differentially expressed cDNA pattern was visualized by exposure of 
the gel to X-ray film. 
2 . 2 . 2 . 3 . 3 . Reampl i f icat ion of cDNA probes 
The DNA from differentially expressed bands was extracted by dissolving in 3M 
sodium acetate, lOmg/ml glycogen and absolute alcohol. Then, the pellet was 
dissolved in water and used for reamplification. The cDNA was reamplified by using 
the same primer set and PCR conditions except the dNTP concentration was 2 / /M and 
no radioisotopes was added. The reamplified PCR products were run on 1.5% agarose 
gel and stained with ethidium bromide. The PCR products was extracted from the 
agarose gel using QIAEX gel extraction kit only when the size of PCR products was 
consistent with that in the differential display gel. 
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2 . 2 . 2 . 3 . 4 . Subc loning of differential ly expressed cDNAs 
A. Preparation of ultra-competent E.coli cells for transformation 
DH5 a cells were cultured in SOB medium containing 0.5% yeast extract, 2% tryptone, 
lOmM NaCl, 2.5mM MgCl2 and lOmM MgSCU at 37°C with vigorous shaking until 
O.D. at 600mn reached about 0.5. The mixture was then placed on ice for 10 min. The 
pellet was collected after centrifugation, washed and resuspended in an ice-cold TB 
solution containing lOmM PIPES, 15mM CaCl� and 250mM KCl. 
B. Preparation of cloning vector and DNA transformation 
Blunt ending of pBluescript II SK+ vectors were generated by cutting with restriction 
enzyme EcoRV in the ratio 1:1 at 37°C for 1 h. The linearized vector was incubated at 
72�C for 2 h in the presence of 2mM dTTP and Taq DNA polymerase to generate T-
overhang. The vector was extracted and precipitated by phenol-chloroform, absolute 
ethanol and resuspended in TE buffer. Ligation was carried out at 16�C overnight with 
T4 DNA ligase. Next day, 10//1 ligation product was transformed into ultra-competent 
E.coli cells on ice for 5 min. After transformation, 100/zl of cell was placed on LB 
plate in the presence of 20mg/ml X-gal and 200mg/ml IPTG and incubated upside 
down at 37°C overnight. Only white or pale blue bacterial colonies from LB plate was 
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randomly picked for fiirther screening. 
2 . 2 . 2 . 3 . 5 . Veri f icat ion of cDNA express ion by colony-PCR and 
cDNA probes 
A. Colony-PCR 
Three bacterial colonies from LB plates were randomly picked and lysed with 50 fi 1 
colony lysis buffer containing 0.1% Tween20 in Tris-EDTA buffer by boiling for 10 
min. The supernatant in the cell debris was collected after centrifligation. 2 ji 1 of lysate 
was used for checking the size of cDNA insert through PGR analysis. The parameters 
and condition for PCR were the same as that described for reamplification. The PCR 
products were resolved in 1.5% agarose gel and confirmed by comparing the size of 
cDNA inserts with the corresponding reamplified cDNA fragments. 
Bo Bacterial glycerol stock and plasmid preparation 
After checking the correct size of cDNA inserts, the single colony on LB plate was 
picked and grown up in 4 ml of SOB medium at 37�C overnight. Then, 1 ml of 
glycerol and 1 ml of bacteria were mixed together and stored at -70�C as the stock. The 
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remaining 3 ml of SOB medium was used to collect the plasmid insert DNA by 
QIAGEN mini-preparation kit. 
C. cDNA probes preparation for Northern blot analysis 
cDNA insert was amplified by PCR with the same parameters in colony-PCR and 
resolved in 1.5% agarose gel. Then the cDNA inserts were cut and purified by QIAEX 
gel extraction kit. This cDNA inserts were used as the probe for Northern blot analysis. 
2 . 2 . 2 . 3 . 6 . Northern blot analys is 
Total RNA of A431 cells was prepared as described in section 2.2.2.2. 10//g of total 
RNA was run in 1% agarose/7M formaldehyde denaturing gel and transferred to nylon 
membrane overnight. The membrane was cross-linked by UV light before 
hybridization. The purified cDNA probes were labeled with pP]dCTP using random 
prime labeling system. The membrane was equilibrate4 in 2X nucleic acid transfer 
buffer (SSC) and pre-hybridized in 10ml Rapid-hyb buffer at 65�C for 30 min in a 
hybridization oven. The cDNA probes was denatured at 100°C for 5 min and kept on 
ice. Then it was labeled with 5/zl [^^P]dCTP by Redprime DNA labeling system. The 
cDNA probe was incubated 耽 37°C for 10 min and the reaction was stopped by adding 
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5//I 0.2M EDTA. The radiolabeled cDNA probe was denatured at 100°C for 5 min, 
kept on ice for 5 min and mixed with Rapid-hyb buffer. The radiolabeled cDNA probe 
was hybridized with the pre-hybridized membranes at 65�C for 2 h. The membrane 
was washed with SDS-containing water at 65°C for 20 min once and then 15 min twice. 
After stringent washes, the pattern of mRNA expression was visualized by exposure of 
membranes to X-rays film with intensifying screen at -70°C. 
2 . 2 . 2 . 3 . 7 . Sequenc ing of the c loned cDNA inserts 
After confirmation of the expression patterns in Northern blot analysis with the 
expression patterns observed in differential display, the clone was then sequenced with 
automatically ABI PRISM dRodamine Terminator cycle sequencing ready reaction kit 
by using Ml 3 (-20) and Ml3 reverse primers (pBluescript II SK+ phagemid vector) as 
sequencing primer pairs. The resulting sequence was aligned with the Genbank 
database using BLAST search. 
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Figure 2.1. Schematic drawing of differential hybridization of human cDNA 
Genefilters Microarray. mRNAs were extracted from exponentially growing A431 
cells and were reverse-transcribed and radiolabeled with [^^P]dCTP as described in the 
methodology. The radiolabeled cDNA from both parent and drug-resistant cells, AlOA 
and CP500N, were hybridized with membranes of human cDNA microarray 
(Invitrogen Corp., USA) in parallel at 42°C. The signals were detected by phosphor 
imaging and analyzed by Pathway 4 software (Invitrogen Corp., USA), 
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Figure 2.2. Schematic drawing of mRNA differential display protocol. Total RNA 
from exponentally growing A431 cells were extracted and DNA contamination was 
removed by treating RNA with DNase I from MessageClean kit (GenHunter Corp., 
USA). Equal amount of RNA from A431 cells were reverse transcribed to generate 
first strand cDNA by using oligo-dT primers, followed by PGR reaction in the 
presence of a second arbitrary primers provided in the RNAimage kit (GenHunter 
Corp., USA). The amplified and radiolabeled cDNAs were resolved in 6% denaturing 
polyacrylamide gel electrophoresis and visualized by autoradiography. Bands that are 
unique or differentially expressed were extracted and reamplified by PGR and later 
subcloned into pBluescript vector and their expression patterns were verified by 
Northern blot analysis. 
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Table 2.2. Primers used in mRNA differential display and subcloning 
1. One-base-anchored oligo-dT primer 
H-TiiG : 5AAGCTTTTTTTTTTTG-3‘ 
H-TiiA : 5，-AAGCTTTTTTTTTTTA-3， 
2. Arbitrary primers: 
H-AP 12 : 5，-AAGCTTGAGTGCT-3， 
H-AP 19 : 5，- AAGCTTATCGCTC-3 ‘ 
3 . Primers u s e d for Colony-PCR and sequenc ing of inserts 
sub-c loned in pBluescript II SK+ vector : 
M13 forward : 5，-GTAAAACGACGGCCAGT-3， 
M13 reverse : 5，-GGAAACAGCTATGACCATG-3’ 
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/ pBluesrdpt II \ 
KS (+/-) 
\ Phagemid vector I 
\ 2.9kb J 
X MCS lacZ f l (+) o r i g i n 诸 乂 现 
_ L _ � — _ 
/ M 13 (R) ^ ^ ^ ^ ^ 
GGAAACAGCT ACCATG T DNA 八 ACTGGCCGTCGTTTTAC 
CCTTTGTCGA ^TGGTACT A Insert x TGACCGGCAGCAAAATG 
B -Galactosidase — ^ ^ 
M 13 (F) 
Figure 2.3. Structure of pBluescript II SK(+/-) vector. pBluscript vector contains a 
portion of lacZ gene for a -complementation. When no insert is present, a fiinctional 
a -peptide is produced that complements results in production of functional j3 -
galactosidase protein. Therefore, blue colonies will appear on LB plates containing 
IPTG and X-gal. When the DNA insert into the vectors, the lacZ a -peptide will be 
interrupted and no complementation occurs and the colonies will appear in white color. 
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2.3. RESULTS 
2.3.1. Differential gene expression profile of A431 cells 
ResGen GeneFilters� cDNA microarray was employed to study the differential gene 
expression profile among different A431 cells. Alteration of these genes may be 
associated with drug resistance mechanism in human squamous carcinoma A431 cells. 
The pattern of gene expression profile in A431 cells was shown in Figure 2.4. Each 
gene is represented by dots on the array. After the import of images to Pathway 4 
software, the differential expression pattern of cDNA in A431 parent cells, drug-
resistant AlOA and CP500N cells on the array was shown in Figure 2.4. The list of 
genes and their GenBank accession numbers on the microarray are available at 
ResGen's web site (http://www.resgen.com). After the comparison analysis by 
Pathway 4, the data were shown in the format of a synthetic microarray which has the 
colored spots that are arranged in the same pattern as that of the microarray. The 
microarray images after comparison showed upregulation or downregulation by the 
color. Upregulation (high ratio) was shown in green color while downregulation (low 
ratio) was shown in red. Besides, the data can also be presented in scatter plots with 
defined axis (Y-axis: ratio, X-axis: clone numbers) (Figures 2.5). The gene expression 
ratio has shown in Table 2.3. The gene is considered to be differentially regulated if 
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the ratio between the parent and drug-resistant cell lines is greater than 2 or less than 
0.5. Among all the genes on the membrane, signals corresponding to 85 genes were 
differentially expressed when comparing parent with either AlOA or CP500N cells. 17 
genes were overexpressed in AlOA or CP500N cells and 68 were overexpressed in 
A431 parent cells. The rest of the genes had similar expression level or beyond the 
limit of detection by image analysis programme. 
From the above analysis, cDNA microarrays allowed the identification of wide 
categories of genes with altered expression. For example, expression of ribosomal L5 
protein was upregulated in the drug resistant AlOA and CP500N cells. It was found 
that overexpression of this protein was associated with cellular drug resistance and 
stress response in doxombicin-resistant colon carcinoma cells. Some genes such as 
sarcospan (Kras oncogene associated protein) and guanine nucleotide binding protein 
were upregulated in AlOA and CP500N cells. Further investigation in these genes of 
their association with drug resistance in cells is required. 
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Figure 2.4. Comparison of cDNA microarrays from drag-resistant and sensitive 
human squamous carcinoma A431 cells. Hybridization of radiolabeled A431 cDNA 
probe with membrane of ResGene Genefilters human cDNA microarray. The phosphor 
image was analyzed by Pathway software. Each membrane is divided into two fields. 
The position of genes on the array can be recognized as the grid A to H. The grids are 
then organized into 12 columns and 30 rows. The complete list of genes was shown on 
Invitrogen Corporation web site. 
Cell lines: P: A431/parent cells; A: A431/A10A cells; N: A431/CP500N cells 
Color: Green: upregulation; Reds downregulation 
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c. 
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Figure 2.5. Comparison of expression levels of genes in the drag-resistant and 
sensitive human squamous carcinoma A431 cells by scatter plot. X-axis indicated 
the number of clones in the cDNA microarray. Y-axis indicated the ratio between the 
gene expression levels of drug-resistant / parent A431 cells. A. Spots in blue color 
represented the expression ratio between AlOA / A431 parent cells of each gene. B. 
Red spots represented the expression ratio between CP500N / A431 parent of each 
gene. C. Synthetic scatter plot for comparison of both A431 parent and drug-resistant 
cells. Gene with ratio of greater than 2 or less than 0.5 was considered to be 
differentially upregulated or downregulated respectively. Genes with similar levels of 
expression had the ratio lies near or equals to 1. 
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Table 2.3A Genes over-expressed in A431 parent cells 
Gene Location Ratio 
in expression 
A/P * N/P 
v-rel avian reticuloendotheliosis viral oncogene homology A 1, c, 25, g 0.165 
v-rel avian reticulo endothelio sis viral oncogene homology B 1, b, 22, g 0.277 0.279 
Carboxylesterase 1 1, c, 25, 2 0.239 
DR-1 associated protein 1，b, 13, 1 0.274 
Phosphorylase kinase, beta 2，e, 4，3 0.283 0.253 
Beclin 1, b, 26, 11 0.294 
Neurofilament 3 2，g 10，5 0.299 0.253 
Tetracycline transporter-like protein 1, e, 14,9 0.305 0.311 
Glycyl-tRNA synthetase 1, c, 16’ 9 0.307 0.343 
Mitogen-activated protein kinase kinase 4 1, d, 20, 12 0.311 
Protein phosphatase IG, gamma isoform 1，b, 24’ 9 0.313 0.368 
Mitochondrial intermediate peptidase 1,d, 21, 8 0.320 
Cofactor required for Spl transcriptional activation, subunit 9 1，d, 22，9 0.322 
Mitogen-activated protein kinase-activated protein kinase 2 1, f, 5, 12 0.322 0.330 
Mannose phosphate isomerase 1, g, 4,5 0.326 0.345 
CDS antigen, alpha polypeptide 1,e 10, 4 0.333 
Methionine aminopeptidase, elf-2-associated p67 1，a, 19，1 0.338 
Sialytransferase 4C 1,g, 30, 11 0.341 0.380 
Elasterase 3, pancreatic 1,h, 13，8 0.350 0.356 
Amylase, alpha 2A, pancreatic 1, f, 8,2 0.357 0.364 
Tumor susceptibility gene 101 2, e, 21,4 0.377 0.260 
Melan-A 2, e, 8，4 0.379 0.337 
ATP-binding cassette, sub-family C, member 1 1，g, 1，10 0.381 0.408 
Kinesin-like 1 1,e, 19,9 0395 
Fc fragment of IgE 2，f，20，3 0.403 0.389 
Integrin beta 3 1,f, 25,7 0.412 
Ubiquitin-conjugating enzyme E2E 1 1’g，6,9 0.420 0.399 
Potassium intermediates 1, f, 19, 9 0.421 0.348 
Gamma-glutamyl hydrolase 1, h, 22, 10 0.424 0.330 
Postmeiotic segregation increased 1 1, e，20，9 0.424 0.341 
Brain-derived neurotrophic factor 1, f, 9, 4 0.435 
Serine proteasae inhibitor, krazal type 2 1, c, 8，8 0.436 
Insulin-like growth factor 2 1, g, 12, 11 0.438 0.288 
Major histocompatibility complex, class II 1, b, 10,2 0.442 0.352 
Peptidylprolyl isomerase B 1, e, 19,6 0.443 0.479 
Arylalkylamine N-acetyltransferase 1，a, 30,8 0.443 0.488 
RNA binding motif protein 5 |l，e, 10,10 I 0.447 | 0.461 
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Gene Location Ratio 
in expression 
A/P * N/P 
Integral membrane protein 1 1,f，28，7 0.453 0.390 
Platelet/endothelial cell adhesion molecule 1, h, 22，3 0.463 0.400 
Aldehyde dehydrognase 7 1, h, 22, 7 0.471 
Forkhead box F2 2’e，9,4 0,473 0.374 
Signal transducer and activator of transcription 3 1 ,a, 29，2 0.473 0.473 
Cytochrome P450, subfamily IIIA, polypeptide 7 1, a, 13,4 0.473 0.421 
Leukotriene A4 hydrolase 1, h, 1,5 0.475 0.489 
Diacylglycerol kinase, delta 1，f, 22,5 0.477 0.363 
Mitochondrial capsule selenoprotein 2, h, 8，6 0.478 0.430 
Protease inhibitor 8 2，h，3,6 0.482 0.462 
POU domain, class 6，transcription factor 1 1, e, 21 ’ 6 0.491 0.431 
Macrophage stimulating, pseudogene 9 1, h, 19,6 0.497 0.422 
Synuclein, gamma (breast cancer-specific protein 1) 1, f, 19,6 0.499 0.487 
Adrenergic, beta-2, receptor, surface 1，a, 29,7 0.253 
Thymosin, beta 10 1, g, 12, 12 0.256 
Secroteogranin II 2，a, 23，4 0.285 
Zinc finger protein 137 1,d, 11,6 0.321 
Antiquitin 1 1,f，12,12 0.366 
B7 protein 2,f, 9，7 0.382 
Splicing factor 3a，subunit 1 1,d, 27,11 0.405 
Homo sapiens agrin precursor mRNA, partial compounds 2,b, 17, 7 0.408 
Serine/theronine kinase 18 1，f, 25，8 0.427 
Cytochrome b-245, beta polypeptide 1，b，25，5 0.435 
Aquaporin 1 2,g, 29，6 0.440 
ITBA-1 gene 1,g, 28, 11 0.446 
Retinoic acid receptor, alpha 1，e，19，8 0.456 
Catechol-O-methyltransferase 1’b，17,2 0.463 
Eukaryotic translation initiation factor 5 1,g, 11, 7 0.463 
Transmembrane 4 superfamily membrane 1 1’f’ 18，12 0.478 
GTP cyclohydrolase I feedback regulatory protein 2,g, 13’ 5 0.491 
Ribosomal protein L13 I U 24，9 0.495 
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Table 2.3B Genes over-expressed in drug resistant AlOA and CP500N cells 
Gene Location Ratio 
in expression 
A/P* I N/P 
Beta actin 一 2,c，17，1 2.032 
Lactate dehydrogenase 1,c，13，1 2.047 
Ribosomal protein L30 1，a, 17, 9 2.067 
Sarcospan (kras oncogene-associated protein) 2, c, 19, 6 2.083 
Calmodulin 2 2，b, 23, 1 2.154 
Membrane-spanning 4-domains, subfamily A, member 2 2,d, 16,3 2.278 2.115 
Ribosomal protein L5 l,d, 2,6 2.311 2.279 
Synaptopodin 2, d, 5,6 2.036 2.326 
Catecho 1-0-methy lytransferase 2，c, 13’ 1 3.556 
Major histocompability complex, class 1 2，d，13, 1 3.654 4.667 
Plasminogen activator inhibitor, type II 1,g, 30, 6 6.156 
Voltage-dependent anion channel 1,d, 14,6 2.169 
SlOO calcium-binding protein 1,h, 16，6 2.216 
Tyrosine 3 -monoxygenase/tryp 5 -monoxygenase activation 2.435 
protein 2’a, 3, 6 
Thymosin, beta 4, X chromosome 2,f, 20，4 2.678 
Guanine nucleotide-binding protein (G protein) 2,b, 14’ 1 2.794 
Beta-2-microglobulin 1,a, 15, 9 3.245 
* Ratio: the numerical value of the Normalized Intensity of a spot on a microarray in a 
microarray pair (P and A/ P and N) divided by the Normalized Intensity of the same 
spot on a second microarray. 
Cell lines: P: A431/parent cells; A: A431/A10A cells; N: A431/CP500N cells. 
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2.3.2. Identification of differentially expressed genes by mRNA 
differential display 
In order to investigate any novel genes that may be related to drug resistance 
mechanisms in A431 cells, A431 parent cells were analyzed in parallel with DOX- and 
CP-resistant cells, AlOA and CP500N, for comparative study of gene expression 
profile by differential display. The oligo-dT primer H-TnA and H-TuG were used in 
combinations with 2 arbitrary 13 mer primers H-AP19 and H-AP 12 respectively for 
RT-PCR. After poly aery lamide gel denaturing electrophoresis, the gene expression 
profile of A431 cells was displayed and visualized by autoradiography (Figure 2.6). 50 
bands were identified with differential expression among A431 cells and were 
retrieved for reamplification. Twenty-eight of them were reamplified successMly 
(Figure 2.7) and 10 was subcloned into pBluescript vector and verified by colony-PCR. 
While the remaining clones were found to have no insert sequence in the vectors (blue 
colonies in the agar plates) or no bands after colony-PCR was performed. The cDNA 
probes were prepared for Northern blot verification. Five of them were confirmed as 
differentially expressed and the remaining were found to be false positive or no signal 
on the Northern blot analysis. The expression patterns verified by Northern blot were 
presented in Figure 2.8. After confirmation, the clones were subjected to DNA 
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sequencing and the sequence was then aligned with the Genbank database by BLAST 
search as summarized in Table 2.4. 
Among the 5 sequenced cDNA clones, 1 of them was novel and 4 were known genes. 
The functions of those genes were diverse. These include RNA synthesis (ribosomal 
protein S7), DNA binding (zinc finger protein 189), cellular signaling 
(phosphodiesterase 8A) and proton translocation in cells (vacuolar proton pump 
subunit c). Some of these genes identified were chosen for further characterization of 
their roles in drug resistance mechanisms and the results were presented in the 
following chapters. 
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Figure 2.6. Differential display was performed using one-based anchored oiigo-dT 
primer H TnG (Left) and H-TnA (Right). Equal amount of DNA-free A431 RNA 
was reverse transcribed and amplified by PCR in combination with arbitrary primers 
H-AP12 and H-AP9. The gene expression profiles of A431 parent and drug-resistant 
cells were compared in 6% polyacrylamide gel electrophoresis. Arrows indicated the 
examples of differentially expressed bands. 
Cell lines: P: A431/parent cells; A: A431/A10A cells; N: A431/CP500N cells. 
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Figure 2.7. Reamplification of cDNA bands extracted from differential display. 
Differentially expressed cDNA fragments were extracted and reampiified by PGR with 
the same primer sets and PGR condition. The size of reampiified cDNA was visualized 
by resolving on 1.5% agarose gel. 5 / / I of successfully reampiified PGR products were 
ligated into pBluescript vector and transformed into competent bacterial E.coli. The 
DNA insert was extracted and purifed as a probe for Northern blot analysis to further 
comfirm the mRNA expression pattern of the clone. The number in blue color 
indicated the cDNA that were chosen for cloning. The expression patterns were 
verified by Northern blot analysis. M: lOObp DNA ladder. 
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Figure 2.8. Northern blot analysis of cDNA clones identified from differential 
display in A431 cells. The differentially expressed cDNA were reamplified and 
subloned into pBluescript vectors. The positive clones were picked and colony-PCR 
was performed. The size of cDNA inserts were confirmed by resolving on 1.5% 
agarose gel and compared with the size of reamplifed cDNA from Figure 2.7. Mini-
preparation of cDNA plasmids was carried out and the cDNA probes were resolved on 
1.5% agarose gel. The probes were purified with QIAEX gel extraction kit and 
H  
radiolabeled with [ P]dCTP by Redprime II random prime labelling system. 
Hybridization of 10 " g A431 RNA on nylon membrane with cDNA probes of interest 
was carried out to verify the gene expression patterns in differential display. The equal 
loading on each lane was shown by the levels of 18S and 28S rRNA. The size of genes 
expressed in Northern blot was estimated by the relative distance of corresponding 
genes to 18S and 28S rRNA on the same blot. 
Cell lines: P: A431/parent cells; A: A431/A10A cells; Ni A431/CP500N cells 
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Size of Estimated 
Name of Expression cDNA size of 
cDNA clone pattern from gene from HomoSogy of gene Accession 
DD gel NB (b.p.) sequence Number 
(b.p.) 
H.S. Ribosomal protein 
AA-7P19 A>N>P 355 729 S7 (RPS7): (99% reFNM_001 
homology) 011.2 
H.S. Hypothetical protein 
FLJ23277 fis, done 
PA-8F19 P>A�N 347 2120 HEP03322: dbj/AK—026 
(99% homology) 930.1 
H.S. Zinc finger protein 
189 (ZNF 189): 




NA13P19 N~A>P 296 3396 (PDE8A): gb/AF05649 
(98% homology) 0.1/AF0564 
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H S. ATPase, H+ 
transporting lysozyme 
(vacuolar proton pump) 
NG-274P12 N>A>P 125 1126 16kDa, VOsubunit c: re頻M_001 
(100% homology) 694.2 
Table 2.4. Summary of differentially expressed cDNA cloned and sequenced in 
A431 cells. The sequence was aligned with the Genbank database by BLAST search. 
Cell lines: P: A431/parent cells; A: A431/A10A cells; N: A431/CP500N cells 
DD: differential display; NB: Northern blot analysis; HS: homo sapiens 
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2.4. DISCUSSION 
Drug resistance is a major problem encountered in cancer chemotherapy. Alteration of 
various genes during tumorigenesis may also influence cellular sensitivity to 
chemotherapeutic drug (El-Deiry, 1997). Studying these genetic alterations may 
provide an alternative pathway of exploring novel molecular mechanisms, other than 
the conventional known mechanisms, in identifying new targets in modulating drug 
sensitivity or altering drug resistance pathway. The aim of the study was to investigate 
and identify differentially expressed genes between A431 parent and drug-resistant 
cells, AlOA and CP500N. Global profiling of gene expression at the genomic levei 
using powerful DNA microarrays and mRNA differential display were employed in 
the study. Both techniques provide invaluable information in understanding the drug 
resistance mechanisms and help to design more effective treatment strategies to 
circumvent resistance. 
Differentially expressed genes among A431 cells were identified by cDNA microarray 
and mRNA differential display. Eighty-five genes were observed of which 17 genes 
were upregulated in AlOA or P500N cells in microarray�Most of the genes cannot be 
detected on the array, this may be due to the low abundance of the transcripts in the 
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mRNA pool or some of these genes were not expressed at all. Besides, genes related to 
tumorigenicity like tumor susceptilibity gene 101, drug detoxifying gene like 
cytochrome P450 subfamily IIIA (CYP3A), intracellular transducers like mitogen-
activated protein kinase kinase 4 (MAPKK4), mitogen-activated protein kinase-
activated protein kinase 2 were upregulated in A431 parent cells. Although their role in 
drug resistance is still unknown, other genes in their families were known to be 
associated with drug sensitivity or resistance in tumor cells (Weldon et al., 2002, 
Murray et al., 1993, Rochat et al, 2001, Martinez et al., 2002). The information 
provides a hint in identifying new targets related to drug resistance mechanisms. 
Further confirmation by Western blot analysis and RT-PCR are required to verify their 
expression. 
Using combinations of 2 arbitrary primers (HAP-12, -19) and 2 one-base anchored 
oligo-dT primers (H-TnG/A) by differential display, one novel and four known genes 
were identified and confirmed by Northern blot analysis. Alteration of their expression 
may be induced during (Jmg selection or induction and this may correlate with the 
changes in modulating drug sensitivity in cells. Two clones were selected for further 
characterizing of their role and the results will be presented in Chapters Three and Four. 
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The genes identified from differential display provide an alternative pathway in 
studying drug resistance in cells. 
Although both tools, micoroarray and DD, are well known and powerful for analyzing 
gene expression level, there are some limitations for these methods. For microarray, 
one is limited by the detection of whatever genes that are spotted on a membrane, 
making it a "closed" system for gene discovery. Therefore, any new genes or novel 
drug resistance mechanisms cannot be explored. Also, potential hazards such as high 
-J� 
background and the use of radioactive substances ( P) for probe labeling and 
hybridization were encountered. It is also time consuming in analyzing a large amount 
of microarray data and verified by Western blot. Northern blot or RT-PCR. It was 
suggested that chemiluminescent analysis would be an alternative for low background 
and minimal hazards. Moreover, the use of DIG (digozigenin)-dUTP labeled cDNA 
probes allows storage and reuse of labeled samples. Also, the signal on the membranes 
can be stripped easily after hybridization and maintaining low background on the 
arrays for reuse (Rajeevan et al., 1999). 
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The cDNA microarray in the study was limited by discovering "closed" system in drug 
resistance mechanims, therefore, another tool, mRNA differential display, was 
employed to identify novel drug resistance mechanisms in A431 cells. The low 
quanitity of starting materials and the ability to simultaneously analyze multiple 
samples were the advantages of this technique. However, high false-positive rates have 
been reported (Li et al, 1994, Sun et al., 1994). There are two main causes of false 
positives, 1) identical-size DNA fragments that co-migrate with the band of interest on 
the display gels and 2) DNA contamination introduced into the reamplification PCR 
(Miele et al , 1998). After standard 40 cycles of PCR reamplification, the co-migrating 
species will be amplified to equivalent to the real candidate cDNA (Liang and Pardee, 
1992). It has been suggested that single-strand confirmation polymorphism (SSCP) can 
be used to purify the cDNA fragments containing the co-migrated product before 
subjected to reamplification and subcloning (Callard et al” 1994). 
In order to minimize the generation of false positive clones and increase the 
reproducibility of expression patterns, precautions and improvement should be taken. 
cDNA should be freshly prepared for separating on the denaturing polyacrylamide gel 
to improve the resolution. Also, preparing core mix for PCR reaction, keeping PCR 
I 
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reaction mix on ice before performing PGR and maintaining the same experimental 
conditions can improve the reproducibility. Moreover, ^^P-labeled primer can replace 
35 
the use of S in differential display in order to increase the sensitivity without 
affecting band resolution. Since ^^ P has higher energy than ^^S, so exposure time of 
autoradiography can be reduced (Tokuyama and Takeda, 1995). Other methods such as 
fluorescence-based differential display which accompanied with the programmable 
genomyxLRTM dNA sequencer provide a more safe method to replace the hazardous 
radioactive materials. Also, it can provide high-resolution gel analysis and precision of 
cDNA retrieval using computerized technique (Ito et al” 1994, Reinhardt et al., 1999). 
As a tool for detecting global changes in gene expression, differential display has many 
advantages, compared with other technologies, and it has proven that it can rapidly 
screen the transcriptome for changes in gene expression. Furthermore, it is a relatively 
simple and inexpensive technology that can be rapidly established in any laboratory. 
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CHAPTER THREE 
Characterization of Differentially Expressed 
Genes Identified by Differential Display: 
Part 1: The role of vacuolar proton pump in 




3.1.1. An overview of vacuolar proton pump / vacuolar ff'-ATPase (V-
ATPase): Structure and function 
Cells have evolved various transport proteins that are responsible for controlling the 
ion and solute composition of cytoplasm. One cellular parameter which is particularly 
important is pH. Whereas cytoplasmic pH is crucial for cellular process such as growth 
control and metabolism as many of these processes require a narrow optimal pH. 
Indeed, cytoplasmic pH is also important in tumorigenesis (Perona et al., 1988), 
metastasis (Schlappack et al., 1991) and drug resistance (Thiebaut et al., 1990, 
Martinez-Zaguilan R et al., 1999) in cancer cells. Difference in pH between drug-
sensitive and drug-resistant cells appears to be critical to the therapeutic effectiveness 
of anticancer agents. pH regulators, proton pump (vacuolar H^-ATPase), has been 
identified in tumor cells. By understanding the structure and fiinction of the pump, it 
may help in investigating their role in drug resistance in cells. 
In the early 1980s, V-ATPase was discovered (Nelson, 1992) and found to be a 
universal component of eukaryotic organisms (Finbow and Harrison, 1997, Forgac, 
1998, 1999). It is present in the membranes of many organelles including vacuoles, 
endo somes, ly so somes and secretory vesicles (Merzendorfer et al., 1997, Wieczorek et 
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al., 1999), but also in the plasma membrane such as macrophages, osteoclasts and renal 
intercalated cells. The V-ATPases are proton-translocating enzymes which pump 
protons from the cytoplasm to the lumen of vacuole using the energy released by ATP 
hydrolysis. It is the major electrogenic pump of vacuolar membranes creating an 
electric potential difference across the membrane (Torigoe et al., 2002). They are 
required for maintaining cytoplasmic pH and also play an important role in 
acidification of intracellular compartments, such as clathrin-coated vesicles, 
endosomes, lysosomes and Golgi derived vesicles (Mellman et al., 1986, Ami et al., 
1987). Vacuolar acidification is important for a variety of cellular events, such as 
release of internalized ligand from receptors, viral infection, degradation of 
macromolecules, transport of small molecules into vesicle lumens and activation of 
transcription factors (Torigoe et al., 2002). In addition to their role in intracellular 
compartments, the V-ATPases are important for plasma membrane functions in 
various specialized cells. For examples, in kidneys and osteoclasts, they are important 
in homeostatic mechanism and bone degradation respectively (Vaananen et al, 1990, 
Gluck, 1992). 
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The V-ATPases belong to a class of pumps that includes the familiar mitochondrial 
FoFi- type ATPase (F-ATPase) and gastric ATPase (P-ATPase). While the primary 
structures of these types of ATPase show an evolutionary relationship, the types differ 
with respect to their function (Torigoe et al., 2002). The V-ATPases are 830 kDa 
multisubunit complexes composed of two functional domains: a membrane-extrinsic 
Vi domain and a membrane-embedded Vq domain. The ATP-hydrolyzing Vi domain is 
a 570 kDa peripheral complex of eight different subunits (Subunits A to H). The 
proton-translocating Vq domain is a 260 kDa integral complex of five different 
subunits (a, c, c', c", d) (Figure 3.1). All the core subunits of the V-ATPase have now 
been identified and much is known about the assembly, regulation and pharmacology 
of enzyme. Recent genetic analysis has implicated the V-ATPase to be a vital 
component of higher eukaryotes (Finbow and Harrison, 1997). 
Several inhibitors have been found to interact with V-ATPases, interfering with both 
ATP hydrolysis and proton translocation activities. In the past, 
dicyclohexylcarbodiimide (DCCD), N-ethylmaleimide (NEM) and 7-chloro-4-
nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) were the only inhibitors for V-ATPases, 
although DCCD also affects F-ATPases. With the discovery of bafilomycin Al 
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isolated from Streptomyces griseus and concanamycin A isolated from Streptomyces 
diastatochromogenes (Kinashi et al., 1984, Bowman et al., 1988) as high affinity 
inhibitors of V-ATPases (at nanomolar concentrations) through blocking of proton 
translocation, it became possible to study specifically the function of this type of 
ATPase. 
3.1.2. V-ATPases and drug resistance mechanisms 
V-ATPases are fiinctionally expressed in plasma membranes of human tumor cells and 
may have specialized functions in cell growth, differentiation, angiogenesis and 
metastasis (Martinez-Zaguilan et al., 1998, Perona et al., 1988)，In recent years, 
expression of V-ATPases and their subunits are shown to confer drug resistance to 
anticancer drugs and modulate sensitivity in cancer chemotherapy. For instance, 
inhibition of V-ATPases by bafilomycin Al induced a major increase in drug 
accumulation and inhibited drug efflux in vincristine or doxombicin-resistant HL-60 
cells (Marquardt and Center, 1991). Altered cytosolic pH (pHi) as regulated by V-
ATPases has been implicated in drug resistance in cells (Moriyama, 1996, Beck, 1987). 
Intracellular acidification, an early event in apoptosis, increased susceptibility of cells 
to killing by chemotherapeutic agents such as etoposide and camptothecin (Barry et al, 
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1993, Goossens et al , 2000). This indicated that intracellular acidification activates 
endonucleases and subsequently induces cellular DNA fragmentation. These data 
suggested that the V-ATPase may be a promising molecular target for therapy as it 
induces escape from apoptosis caused by many stresses including anticancer drugs. 
Moreover, upregulation of proton pump gene was found in cisplatin, vincristine and 
etoposide-resistant epidermoid KB cells and its inhibition could modulate the cellular 
pHi and potentiate the cytoxicity of cisplatin (Murakami et al., 2001). 
3.1.3. Objective 
In Chapter Two, mRNA differential display was used to compare the gene expression 
among parent, cisplatin- and doxorubicin-resistant A431 cells, in the search of novel 
mechanisms that may involve in the development of cisplatin and doxorubicin 
resistance. One of the clones, vacuolar proton pump subunit c gene, was found to be 
overexpressed in cisplatin-resistant CP500N cells. V-ATPases are proton-pumping 
enzymes and are responsible for maintaining cytoplasmic pH. Alteration of pHi has 
been observed during the process of tumorigenesis and apoptosis in various cancer 
cells. But whether the alteration of pHi controlled by V-ATPase may involve in drug 
resistance of A431 cells has not been investigated. To explore the role of V-ATPase in 
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regulation of drug sensitivity in A431 ceils, the influences of V-ATPase inhibitors, 
bafilomycin Al and concanamycin A, on cisplatin and doxombicin-induced DNA 
fragmentation were determined and discussed in this Chapter. 
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Figure 3.1. Diagram of subunits and domains of vacuolar H^-ATPase. V-ATPase 
is a 830 kDa multisubunit enzyme which is composed of the cytosolic sectors Vi 
domain (570kDa) and the membrane sector Vo domain (260 kDa). The Vi domain 
(subunits A — H) hydrolyzes ATP and the Vo domain (subunits a, c, c,, c" and d) 
translocates protons. 
72 




diphenyl-tetrazolium bromide (MTT) Sigma 
• 5-(and-6)-carboxy SNARF�-1, 
acetoxymethyl ester (SNARF) Molecular Probes 
• Bafilomycin Al Calbiochem 
• Concanmycin A Calbiochem 
• Chloroform BDH Laboratory Suppliers 
• Cisplatin Sigma 
• Dimethyl sulfoxide (DMSO) Sigma 
® Doxorubicin Sigma 
• Ethanol BDH Laboratory Suppliers 
• Ethidium bromide Sigma 
• Ethylenediamietetraacetic acid (EDTA) USB 
• Isoamyl alcohol Sigma 
• Nigericin sodium salt Sigma 
• Phosphate buffer saline (PBS) Invitrogen Corp. 
• mRNA differential display system Please refers to Materials in 
Chapeter Two 
Instruments Company 
® FACSORT flow cytometer Becton Dickinson 
® Mini-Protean II electrophoresis apparatus Bio-Rad 
• UV transilluminator UVP 
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3.2.2. Methods 
3 .2 .2 .1 . Cell culture and cell l ines 
Human squamous carcinoma A431 cells, and its sublines were cultured in Dulbecco 
modified Eagle ' s medium supplemented with 10% fetal bovine serum and 5mM L-
glutamate in 3 7 � C humidified 10% CO2 incubator. 
3 .2 .2 .2 . RNA isolation, mRNA differential display, cDNA 
reamplif icat ion and colony-PCR verif ication 
RNA was extracted by lysing exponential growing cells with TRI reagent as described 
in Chapter 2. DNA contamination in the RNA sample was removed with 
MessageClean kit and subsequently RNA image kit (Genellunter Co.) was used for 
differenlial display. Detailed protocol of differential display, cDNA reamplification, 
subcloning and colony-PCR verification were described in Chapter 2. The arbitrary 
primer H-APl 2 and one-based anchored oligo-dT primer H-T | iG was used for 
ditYerential display. The differentially expressed bands were retrieved, reampiified and 
subcloned using pBluescript vector. After confirmation by Northern blot analysis, true 
positive clones were sequenced and the sequences were aligned using BLAST from 
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GenBank. The primers used for identification of the human vacuolar proton pump 
subunit c gene were H-AP 12 and H-TuG (Table 2.1). 
3 . 2 . 2 . 3 . Cellular pH m e a s u r e m e n t by flow cy tometry 
Exponentially growing cells were treated with different concentrations of anti-cancer 
drugs and inhibitors for 2 days. Cells were harvested by trypsinization and washed 
with serum free medium. Finally, 5X10^ A431 cells that were used for pH calibration 
were resuspended in different pH buffer containing lOmM HEPES, 140mM KCl, 5mM 
NaCl, 2.5mM MgCli, 2.5mM CaCli, 0.5mM glucose. 5X10^ cells with drug treatment 
were resuspended in sample buffer containing same composition except the 
concentration of KCl was 5mM. lOmM nigericin was added to the calibration samples 
in order to equilibrate the internal and external cell pH values. Finally, the cells were 
stained with 5 / /M SNARF dye for 30 min in dark at room temperature before flow 
cytometric analysis. Flow cytometric analysis was performed on a FACSort flow 
cytometer and pH value in cells was detected with excitation at 488nm and emission at 
570nm and 640nm. Data acquired were analyzed by software of WinMDI version 2.7 
downloaded from http7/facs. scripps.edu. The ratio between the fluorescence intensities 
at 640nm/570nm is calculated. The pH was estimated from the ratio of emission 
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intensities at two wavelengths, standardizing by comparison with the fluorescence 
intensity ratios of cells whose intracellular pH values was fixed by incubation with 
nigericin. 
3 . 2 . 2 . 4 . MTT Drag Sens i t iv i ty Assay 
A431/P (450), AlOA (1500) and CP500N (1300) cells in 100//I medium were seeded 
in 96-well flat bottom plates for 2 days. Various concentrations of anti-cancer drugs 
and inhibitors (doxroubicin, cisplatin, bafilomycin Al, concanamycin A) were added 
to cells and incubated for 5 days. After incubation, medium in the well was removed 
and 50 1 of 0.1 mg/ml MTT was added and incubated for 3 hours. 150 /z 1DMSO was 
added to each well and incubated at room temperature for 30 minutes. Absorbance was 
read at 570nm in microplate reader. The sensitivity of the A431 cells to drugs was 
calculated as 
% Survival = Absorbance of cells with drug treatment 
Absorbance of control cells X 100% 
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3 . 2 . 2 . 5 . DNA fragmentat ion assay 
A431 cells were grown in 60mm culture dish and treated with different concentration 
of anti-cancer drugs and inhibitors for 3 days. Cells were trypsinized, washed with IX 
PBS and then lysed in lysis buffer containing 5mM Tris-HCl, lOOmM EDTA, 1% SDS 
and proteinase K at 4 5 � C for 2 hours. The DNA was extracted by 
phenol/chloroform/isomyl alcohol (25:24:1) and precipitated with 3M sodium acetate 
and absolute alcohol overnight at -20°C. DNA pellet was collected by centrifiigation at 
14000rpm for 35 minutes by removing the supernatant and was air-dried. The pellet 
was then dissolved in Tris-EDTA buffer (pH8.0) with 0.4 ！i g/ml RNase A overnight. 
40//g of DNA was run on 1.5% agarose gel electrophoresis with IX TBE buffer and 




3.3.1. Identification of a cDNA band encoding vacuolar proton pump 
subunit c by differential display 
NG-274P12, identified by mRNA differential display, was expressed at a higher level 
in cisplatin-resistant CP500N cells than in A431 parent and doxorubicin-resistant cells 
AlOA (Figure 3.2A). The band was retrieved, reamplified by PCR (Figure 3.2B) and 
subcloned into pBluescript vector and the correct size of the insert was determined by 
colony-PCR (Figure 3.2C). The PCR products were about 120bp. The expression of 
this clone was further confirmed to be overexpressed in CP500N cells by Northern blot 
analysis (Figure 3.3A). 
After sequencing, it was determined that clone NG-274P12 was 125 bp in size and had 
100% sequence homology to the 3, end of human vacuolar proton pump (V-ATPase) 
gene subunit c gene (NM—001694) at the region of 855-962 bp (Figure 3.3B). The 
upregulation of V-ATPase subunit gene in CP500N may be associated with the 
mechanism of drug resistance. Further studies in characterizing of its role in inducing 
resistance were shown in the following sections. 
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3-3.2. Effect of bafilomycin Al (BAF) and concanamycin A (CON) on 
DOX- and CP-induced cytotoxicity and apoptosis 
In the study, the V-ATPase subunit c gene was upregulated slightly in AlOA and most 
significantly in CP500N cells by comparing the gene expression between A431 parent 
and its drug-resistant sublines using differential display (Figure 3.2). Since subunit c of 
proton pump is responsible for proton translocation and hence it may be important in 
maintaining and regulating cellular pH in cells. Indeed, there are a number of reported 
instances demonstrating the importance of the V-ATPase in pH regulation and its 
overexpression may influence pHi in cells (Nanda et al., 1992, Wadsworth et al, 1994， 
Heming et al., 1995). To assess whether the overexpression of V-ATPase subunit c 
gene may result in changes in pHi in cells, the cellular pH of A431 cells was measured 
by staining cells with SNARF-AM fluorescence dye using flow cytometric analysis. 
Intracellular pH was estimated from the ratio of emission intensities at the two 
wavelengths. In A431 parent and AlOA cells, cellular pH was about 7.50 and 7.12 
respectively. However, the cellular pH of CP500N cells was increased and closed to 8 
(Figure 3.4 and Table 3.1). The higher pH in CP500N cells appeared to be correlated 
with obvious upregulation of V-ATPase subunit c gene in the cells. 
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Using MTT assay, the differential sensitivity of A431 cells to cisplatin (CP) and 
doxorubicin (DOX) was shown in Figure 3.5. The percentage of cell survival is higher 
in AlOA and CP500N cells than that in the A431 parent cells; the resistant sublines 
appeared to be more resistant to CP and DOX. To understand if V-ATPase will be one 
of the factors responsible for drug resistance in A431 drug resistance cells, the 
influence of V-ATPase inhibitors on drug induced sensitivity were examined. 
Bafilomycin Al (BAF) and concanamycin A (CON) are specific V-ATPase inhibitors 
that can block the proton pumping. The sensitivity of A431 cells to both inhibitors was 
shown in Figure 3.6. It showed that CP500N cells were more sensitive to the inhibitors 
than the AlOA and parent cells. To examine the inhibitory effect of V-ATPase 
inhibitors on drug resistance, A431 cells were treated with different dosage of 
DOX/CP with or without 2nM BAF/lnM CON and cell survival was determined by 
MTT assay. When compared with DOX treatment alone, there was no apparent change 
in survival of cells when treated with DOX together with either BAF or CON (Figure 
3.7). The result showed that the inhibitors had no effect on DOX sensitivity. However, 
when compared with CP treatment alone, cotreatment with either BAF or CON 
decreased cell survival significantly in CP500N cells (Figure 3.8) while there was 
almost no effect in A431 parent and AlOA cells. 
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One of the cytotoxic effects of cisplatin and doxorubicin are believed to be due to the 
formation of DNA fragmentation in tumor cells. Apoptotic cell death induced by drug 
may correlate with the sensitivity of tumor cells to the cytotoxic drug. To determine 
whether the V-ATPase inhibitors may affect drug induced apoptosis and also the effect 
may correlate with the inhibitors effect on DOX and CP sensitivity, the specific V-
ATPase inhibitors, BAF and CON, were used in combination with CP or DOX to test 
their influence on drug induced apoptosis. The effect of inhibitors on DOX/CP induced 
DNA fragmentation was shown in Figure 3.9. As the results indicated, BAF and CON 
had no apparent effect on DOX-induced DNA fragmentation in all A431 cells as no 
obvious change was observed when comparing the cells incubated with DOX alone 
with those with cotreatment. However, both V-ATPase inhibitors enhanced CP-
induced apoptosis in all A431 cells and the enhancement was more obvious in CP500N 
cells that had higher pHi and overexpressed V-ATPase subunit c. The results supported 
the important role of V-ATPase in CP induced cell death in A431 cells. The degree of 
DNA fragmentation induced by CP was related to the level of expression of V-ATPase. 
The results from MTT assay and apoptosis study supported the V-ATPase may be one 
of the determinants for CP resistance while it has no influence on DOX sensitivity in 
A431 cells. 
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Figure 3.2. Identification, reamplifkation，subcloning and cokmy-PCR of the 
cDNA clone NG-274P12 in A431 cells by mRNA differential dispky�（A). Gene 
expression profile of A431 cells as resolved in 6% denaturing polyacylamide gel using 
arbitrary primer H-AP 12 and oligo-dT primer H-TnG. The cDNA fragment that was 
overexpressed in cisplatin-resistant CP500N cells as indicated was named as NG-
274P12. The cDNA was excised for reamplification and subcloning. (B). The 
reamplified PCR product was resolved in 1.5% agarose gel electrophoresis. The size of 
NG-274P12 cDNA was about 120 b.p. (C). The cDNA was subcloned into pBluescript 
vector after reamplification and the size of cDNA insert was verified by colony-PCR. 
The positive colony was picked and grown for bacterial glycerol stock and mini-
preparation of cDNA probe for Northern blot verification. M: lOObp DNA ladder 
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Figure 3.3. Northern blot veiification and sequence of NG-274P12 cDNA clone. 
(A). Hybridization of NG-274P12 cDNA with RNA of A431 cells on nylon membrane 
by Northern blot analysis. The 18S and 28S rRNA indicated the equal loading in each 
lane. (B). The cDNA plasmid was subjected to automatic sequencing by using Ml 3 
forward and reverse primers. The sequence was then submitted to the Genbank 
database by BLAST search. This clone was 125 bp which has 100% sequence 
homology (the underlying region) to the 3, end of human vacuolar proton pump gene 
subunit c gene (NM一001694) with size of 1126 bp. The letters in red at 5' end was the 
H-AP12 primer sequence and that in blue at 3' end was the oligo-dT primer H-TuG 
used in differential display. 
Cell lines: P: A431/pareiit cells; A: A431/A10A cells; N: A431/CP500N cells 
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Figure 3.4. CeOukr pH in A431 parent ceUs, drag-resistant AlOA and CP500N 
cells as measured by using flow cytometiy and carboxy-SNARF-AM. Cells were 
grown for 2 days. For pH calibration, SXloVml cells were trypsinized and resuspended 
in high [K+] buffer at different pH. Nigericin, which acted as ionophore, was added 
into the A431 samples for pH calibration. For cells with drug treatment, they were 
trypsinized and incubated in low [K+] buffer. SNARF-AM dye was added in both 
calibration and drug treatment samples for 30 min in dark and later on flow cytometric 
analysis was performed. 
Cell lines: P: A431/parent cells; A: A431/A10A cells; N: A431/CP500N cells 
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Figure 3.5. Sensitivity of A431 cells to doxorubicin and cisplatin. Cells were grown 
for 2 days before drug treatment. MTT assay was performed after incubation of cells 
with various concentrations of (A) doxorubicin and (B) cisplatin for 5 days. 
Absorbance was measured at 570nm and the percentage of cell survival was calculated 
as the ratio of cells with and without drug incubation. Standard deviation was obtained 
from results of 3 separated experiments as analyzed by Excel Spreadsheet Software. 
The blue line indicated the A431/parent cells. The yellow and pink lines indicated 
A431 sublines, CN and AlOA cells respectively. Cell lines: P: A431/parent cells; A: 
A431/A10A cells; N: A431/CP500N cells 
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Figure 3.6. Sensitivity of A431 cells to both V-ATPase inhibitors by MTT assay. 
Cells were grown for 2 days before drug treatment. MTT assay was performed after 
incubation of cells with various concentrations of (A) bafilomycin Al and (B) 
concanmycin A for 5 days. Standard deviation was obtained from results of 3 separated 
experiments as analyzed by Microsoft Excel Spreadsheet Software. The blue line 
indicated the A431/parent cells. The yellow and pink lines indicated A431 sublines, 
CN and AlOA cells respectively. Cell lines: P: A431/pareiit cells; A: A431/A10A 
cells; N: A431/CP500N cells; V-ATPase: vacuolar proton pump 
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Figure 3.7. Effects of V-ATPase inhibitors, (A) 2iiM bafilomycin Al and (B) InM 
concanamycin A, on DOX sensitivity of A431 cells. Cells were allowed to grow for 2 
days before drug treatment. MTT assay was carried out after incubation of various 
concentration of DOX for 5 days with (pink line) or without (blue line) V-ATPase 
inhibitors, 2nM BAF or InM CON. Absorbance was measured at 570nm and the 
percentage of cell survival was calculated. Cells without drug treatment was set as 
100% viability. Standard deviation was obtained by 3 separated experiments as 
analyzed by Microsoft Excel Spreadsheet Software. 
Cell lines: P: A431/parent cells; A: A431/A10A cells; N: A431/CP500N; DOX: 
doxorubicin; BAF: bafilomycin Al; CON: concanamycin A 
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Figure 3.8. Effects of V-ATPase inhibitors, (A) 2nM bafilomycin Al and (B) InM 
concanamycin A, on CP sensitivity of A431 cells. Cells were allowed to grow for 2 
days before drug treatment. MTT assay was carried out after incubation of cells with 
various concentration of CP for 5 days with (pink line) or without (blue line) V-
ATPase inhibitors, 2nM BAF or InM CON. Absorbance was measured at 570mn and 
the percentage of cell survival was calculated. Cells without drug treatment was set as 
100% viability. Standard deviation was obtained by 3 separated experiments as 
analyzed by Microsoft Excel Spreadsheet Software. 
Cell lines: P: A431/parent cells; A: A431/A10A cells; N: A431/CP500N; CP: 
cisplatin; BAF: bafilomycin Al; CON: concanamycin A 
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Figure 3.9. Effect of vacuolar proton pump inhibitors, 2nM bafilomydn Al and 
InM concanamycin A, on doxorubicin and cisplatin-mduced DNA fragmentation 
in A431 parent (A) and drug-resistant cells, A (B) and N (C). A431 cells were 
cotreated with 0.1 |aM doxorubicin and one of the above inhibitors (left) or cotreated 
with 6 | l iM cisplatin and one of the above inhibitors for 72 hr. Genomic DNA was 
extracted and run in 1.5% agarose gel electrophoresis. M: lOObp DNA marker; Ctl: 
A431 cells with no drug treatment 
Cell lines: P: A431/pareiit cells; A: A431/A10A cells; N: A431/CP500N cells 
Symbols Description  
D Cells treated with doxorubicin 
CT Cells treated with cisplatin  
BAF Cells treated with bafilomycin Al 
CON Cells treated with concanamycin A 
BD Cells cotreated with doxorubicin and 
bafilomycin Al  
CD Cells cotreated with doxorubicin and 
concanamycin A  
BCP Cells cotreated with cisplatin and 
bafilomycin Al  
ACP Cells cotreated with cisplatin and 
concanamycin A  
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3.3.3. Elevation of cellular pH in cisplatin-resistant cells correlated 
with cisplatin resistance mechanism of A431 cells 
From the above studies, it showed that the inhibition of V-ATPase could enhance drug-
induced apoptotic death and modulate the drug sensitivity in A431 parent and CP500N 
cells. This suggested the important role of V-ATPase in cisplatin resistance. V-
ATPases were known in regulating pH in cells. Altered cytosolic pH (pHi) has been 
previously implicated in drug resistance in cancer cells (Beck, 1987, Moriyama, 1996). 
Therefore, a change in cellular pH may be one of the critical parameters in the 
development of drug resistance. It was found that CP500N cells which overexpressed 
V-ATPase subunit c was found to be more alkaline in cytosol than that in A431 parent 
and A cells. It is hypothesized that decrease in pH by inhibition of V-ATPase in A431 
cells would provide an acidic environment in cytosol which is favorable for initiation 
of apoptosis. In order to determine whether it is really the case, the pHi in A431 cells 
upon treatment with CP together with V-ATPase inhibitors were measured by flow 
cytometry. Only A431 parent and N cells were chosen for studying the pHi since the 
V-ATPase inhibition in A cells did not show significant effect on CP induced 
apoptosis and sensitivity. Cellular pH of all A431 cells was altered after the treatment 
of either bafilomycin Al alone or in combination with cisplatin (Figure 3.10). It was 
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previously shown that the cellular pH inN was higher than that in A431 parent in drug 
free medium. When A431 cells incubated with BAF or CP alone, decrease in pH was 
observed in A431 parent and N cells. When the cells were incubated in combination 
with cisplatin and bafilomycin Al, the decrease in pH was observed in A431 parent 
and more significantly in N (Figure 3.10). Lower pH (acidic) in A431 cells may favor 
cytotoxic mechanism of cisplatin since acidification is involved in CP-induced 
apoptosis. In previous sections, cisplatin induced apoptosis was enhanced and directly 
correlated with modulation of CP sensitivity. The significant decrease in pH in 
CP500N after cotreatment indicated that the alteration of pH by suppressing the 
activity of V-ATPase could enhance the apoptosis induced by CP and increase CP 
sensitivity in A431 cells. 
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Figure 3.10. Measurement of cellular pH in A431 cells by flow cytometric analysis. 
Cells were grown for 2 days. For pH calibration, SXlOVml cells were trypsinized and 
resuspended in high [K+] buffer at different pH. Nigericin, which acted as ionophore, 
was added in the A431 samples for pH calibration. For cells with drug treatment, they 
were trypsinized and incubated in low [K+] buffer. SNARF-AM dye was added in both 
calibration and drug treatment samples for 30 min in dark. Flow cytometric analysis 
was performed on a FACSort flow cytometer and pH value in cells was detected with 
excitation at 488nm and emission at 570nm and 640mn. Cellular pH was estimated 
from the ratio between the fluorescence intensities at 640iim/570nm. The number in 
each panel is the cytosolic pH estimated from the ratio using flow cytometric analysis. 




Alteration of gene expression was commonly found in drug resistant tumor cells. This 
may be caused by drug selection or induction during chemotherapy. Studying 
differential gene expression profiles may better understand the molecular mechanism 
of drug resistance. One of the differentially expressed genes, vacuolar proton pump (V-
ATPase) subunit c, was identified by differential display and chosen for fiirther 
characterization of their role in drug resistance. The gene was highly expressed in 
CP500N cells followed by A cells and then A431 parent cells. The expression is 
confirmed by Northern blot analysis. 
The V-ATPases have been identified in tumor cells. Its major ftinction is in 
maintaining cytoplasmic pH. Maintenance of pH is crucial to normal cell function, as 
many cellular processes are carried out in a range of narrow pH. Influence of pH has 
been studied with respect to metastatsis, apoptosis and tumorigenesis (Torigoe et al, 
2002) and some of these processes may affect the response of cells to anticancer drugs. 
Therefore, alteration of V-ATPase activity may likely be one of the important factors 
involved in drug resistance or sensitivity. From the results, N cells were found to be 
more alkaline than A431 parent and AlOA cells. This phenomenon was in comparable 
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with those reported in other tumor cell lines of which the overexpression of V-ATPase 
in cisplatin-resistant KB cells was found to be more alkaline in cytosl than that in 
parent cells (Murakami et al., 2001). 
One of the cytotoxic actions of doxorubicin and cisplatin is believed to be due to the 
formation of DNA adduct and formation of DNA fragmentation (apoptosis) in tumors. 
In order to study the effect of V-ATPase in drug induced cell death in A431 cells, 
specific V-ATPase inhibitors were employed together with DOX or CP. The use of 
2nM inhibitor bafilomycin Al (BAF) and InM concanamycin A (CON) had no effect 
on DOX induced DNA fragmentation. However, both V-ATPase inhibitors enhanced 
CP induced DNA ladder in A431 parent and cisplatin-resistant N cells and the effect is 
less obvious in A cells. Besides, it has proven that the differential response of BAF and 
CON on CP induced cell death was correlated with the change in drug sensitivity 
compared with the anticancer drugs alone (Figure 3.8). The cell viability in combined 
treatment in A431 parent, A and N cells were similar to those cells with DOX 
treatment alone. When the cells were incubated with CP alone or in combination with 
either V-ATPase specific inhibitors BAF or CON, the cell viability in combined 
treatment in N cells was significantly lower than those cells with CP treatment. The 
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enhancement of apoptosis and drug sensitivity in N and A431 parent cells might be 
correlated with cytoplasmic acidification since it was found that acidic pH was 
observed after cotreatment of bafilomycin Al and cisplatin. As it was known that 
intracellular acidification is involved in the initiation phase of apoptosis in response to 
anticancer drug treatment (Barry et al., 1993, Angoli et al., 1996, Gottlieb et al., 1996, 
Iguchi et al., 2002). From the results, low in pH was shown in A431 parent and N cells 
after the combined treatment of BAF and CP for 48 h and the enhancement of CP-
induced apoptosis were obtained for 72 h. This has proven the important role of pH 
affect the drug induced DNA fragmentation. The change in pH towards acidic 
resembles an acidic environment for initiation phase of apoptosis. Therefore, after 
acidification, CP-induced apoptotic death in A431 cells was enhanced and facilitated. 
This suggested V-ATPase might induce intracellular alkalinization in N cells and 
prevent cellular acidosis and thus escape and delay the killing by anticancer drugs such 
as cisplatin. Acidic environment favorites the apoptotic death and increases the 
susceptibility of tumor cells to be killed by cisplatin. Also, the results suggested that 
elevation of cellular pH confers resistance to cisplatin in A431 cells. 
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CHAPTER FOUR 
Characterization of Differentially Expressed 
Genes Identified by Differential Display: 
Part 2: Identification of a Novel cDNA 
Overexpressed in Human Squamous Carcinoma 
A431 Parent Cells 
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4.1. INTRODUCTION 
Acquired resistance to chemotherapeutic drugs is frequently encountered during cancer 
chemotherapy. Recent studies showed that the molecular mechanisms for drug resistance 
are numerous. However, these known mechanisms still cannot fully explain the 
phenomenon of drug resistance in all types of cancer cells. Therefore, further 
investigation is needed. In the present study, a high throughput method, reverse-
transcription polymerase chain reaction differential display developed by Liang and 
Pardee in 1992 (Liang et al., 1992), was employed to identify genes that are differentially 
expressed between A431 parent and drug-resistant cells. The technique is possible to 
determine simultaneously a large part of mRNA transcripts present in an eukaryotic cell 
within a single experiment with high sensitivity. Using mRNA differential display 
approach, an alternative novel drug resistance mechanism in cells may be identified. 
Differential display has opened up new opportunities in various disciplines. This tool is 
also widely applied in elucidation of drug resistance mechanisms. Table 4.1 showed 
examples of some drug-resistant genes identified by differential display. This method 
allowed the identification of drug resistance genes that were not typically described. As a 
result, it provides a new strategy for investigating novel drug resistance mechanism. 
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In the present study, several genes, both known and novel, were identified to be 
differentially expressed in A431 parent and drug resistant cells by differential display. 
The method was described in the previous chapter. One of the known genes were chosen 
for further characterizing for their role in drug resistance in A431 cells as discussed in 
Chapter Three. In this chapter, a novel cDNA clone PA8P-19, which was downregulated 
in both DOX- and CP-resistant A431 cells, was verified by Northern blot analysis and 
chosen for fiirther investigation. The clone was about 347 b.p. and had no sequence 
homology to any of the known gene in the GenBank database. In order to investigate the 
related regulation pathway, the expression pattern of PASP-19 in A431 cells treated with 
DNA damaging agents was studied. Moreover, its expression profile in human tissues 
and tumor cell lines were presented. 
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Drug resistant Anticancer Genes identified References 
cells drugs  
Ovarian cancer taxol Taxol resistance associated Duan et al., 1999 
gene-3 (TRAG-3) | 
Ovarian cancer cisplatin Breast cancer susceptibility Husain et al., 1998 
gene (BRCA-1) • 
Ovarian cancer cisplatin Novel gene • Yamamoto et al., 
I 1998 
Myeloma doxorubicin TRAG-3 f Duan et al., 1999 
Colon carcinoma doxorubicin Melanoma antigen gene Bertram et al, 1998 
(MAGE3) A 
Colon carcinoma doxorubicin Adriamycin-resistant related Kim et al, 1998 
(arr) gene | 
Novel gene t Fanciulli et al., 
• 1996 
Head and neck cisplain T-plastin gene t Hisano et al., 
cancer  
Oral squamous cisplatin Mitochondrial cytochrome C Higuchi, 1999 
carcinoma oxidase subunit II gene 言 
Table 4.1 Examples of both known and novel genes identified by mRNA differential 
display f : gene upregulation | : gene downregulation 
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4.2. MATERIALS AND METHODS 
4.2.1. Materials (Please refer to materials in Chapter 3) 
4.2.2. Methods 
4 . 2 . 2 . 1 . Cell culture and cel l l ines 
Human squamous carcinoma A431 cells, and its sublines were cultured in Dulbecco 
modified Eagle's medium supplemented with 10% fetal bovine serum and 5mM L-
glutamate in 37�C humidified 10% CO2 incubator. 
4 . 2 . 2 . 2 . RNA isolat ion, mRNA differential display, cDNA 
reampli f icat ion and colony-PCR verif icat ion 
RNA was extracted by lysing exponential growing cells with TRI reagent as described in 
Chapter 2. DNA contamination in the RNA sample was removed with MessageClean kit. 
Subsequently, the RNA samples were undergone DD analysis by using RNAimage kit 
(GeneHunter Co.). Detailed protocol of differential display, cDNA reamplification, 
subcloning and colony-PCR verification were described in Chapter 2. The arbitrary 
primer H-AP19 and one-based anchored oligo-dT primer H-TnA was used for 
differential display. The differentially expressed bands were retrieved, reamplified and 
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subcloned using pBluescript vector. The band, named as PA-8P19, was used in the 
study. The correct insert in the vector was checked by randomly picking the white 
colonies in the agar plate and used as a template for PCR reaction. The correct size of the 
insert was confirmed by comparing the size of PCR products with the corresponding 
reamplified cDNA. The identity of cDNA was obtained by automatic sequencing and 
then aligned the sequence in GenBank database. 
4 . 2 . 2 . 3 . Northern blot Analysis 
The procedures of RNA preparation and Northern blot analysis were the same as that 
described in Chapter Two. Cells were grown in 100mm culture dishes for 2 days. Cells 
with no drug treatment were lyzed and used for mRNA differential display and Northern 
blot verification of PA-8P19. To examine the influence of DNA damaging agents on the 
expression of PA-8P19, the cells irradiated at lOGy gamma irradiation or treated with 5 
^g/ml doxorubicin and cisplatin for Ih before they were allowed to grow in drug free 
condition for up to 48h. The expression patterns of PA-8P19 in A431 cells were detected 
by Northern blot analysis. The cDNA probes identified from differential display was 
used for Northern blot verification. The radio labelled cDNA probes were hybridized with 
A431 RNA on nylon membranes and the image were shown by autoradiography. 
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4 . 2 . 2 . 4 H u m a n t i s s u e distr ibution of c lone PA-8P19 
mRNA expression of clone PA-8P19 in human tissue was examined by Northern blot 
analysis. The conditions for the analysis were the same as described. The clone was 
hybridized with human 12 lane Multiple Choice Northern Blots from Origene 
Technologies. The blot containing 2 / /g of polyA+ RNA of 12 human tissues separated 
by denaturing agarose gel and transferred to nylon membrane. Equal loading of polyA+ 
RNA was ensured by normalizing the signal with human -actin cDNA probe that was 
done by the manufacturer. The loading of human RNA was arranged from brain, colon, 
heart, kidney, liver, lung, muscle, placenta, small intestine, spleen, stomach and testis. 
The signal of mRNA on the blot was visualized by exposure to X-ray films. 
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4.3. RESULTS 
4.3.1. Identification of novel cDNA clone PA-8P19 in A431 cells by 
differential display. 
The 8也 cDNA band reamplified by arbitrary primer H-AP19 and oligo-dT primer H-TnA 
was identified to be differentially expressed among A431 cells on 6% denaturing 
polyacrylamide gel (Figure 4.1 A). The band was underexpressed in both DOX- and CP-
resistant, A and N, cells. The cDNA fragment extracted and amplified by PGR was 
designated as PA-8P19. The size of reamplified PA-8P19 was about 350 b.p. (Figure 
4. IB) and was cloned into pBlueScript vector. The correct size of cDNA insert was 
confirmed by colony-PCR amplification (Figure 4.1C). The colony with correct size was 
selected and grown for fiirther mini-preparation of plasmid DNA and glycerol bacteria 
stock. PA-8P19 plasmid DNA was extracted and purified for probe in Northern blot 
analysis. After verification of PA-8P19 expression pattern by Northern blot analysis 
(Figure 4.2A), the cDNA clone was sequenced automatically with ABI PRISM 
dRodamine Terminator cycle sequencing ready reaction kit by using Ml3 (-20) and Ml3 
reverse primers (pBluescript II SK+ phagemid vector) as sequencing primer pairs. The 
resulting sequence was aligned with the Genbank database using BLAST search. There is 
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no homology to any of the known gene submitted in GenBank. The size of clone PA-
8P19 was 347 b.p. and the sequence was shown in Figure 4.2B. 
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Figure 4.1. Identification, reamplification, subcloning and colony-PCR of the cDNA 
clone PA-8P19 in A431 ceils by mRNA differential display. (A). Gene expression 
profile of A431 cells as resolved in 6% denaturing polyacylamide gel using arbitrary 
primer H-AP19 and oligo-dT primer H-TnA. The cDNA fragment that was 
overexpressed in A431 parent cells as indicated was named as PA-8P19. The cDNA was 
excised for reamplification and subcloning. (B). The reamplified PCR product was 
resolved in 2% agarose gel electrophoresis. The size of PA-8P19 cDNA was about 350 
b.p. (C). The cDNA was subcioned into pBluescript vector after reamplification and the 
size of cDNA insert was verified by colony-PCR. The positive colony was picked and 
grown for bacterial glycerol stock and mini-preparation of cDNA probe for Northern blot 
verification. M: lOObp DNA ladder marker; Cell lines: P: A431/parent cells; A: 
A431/A10A cells; N: A431/CP500N cells� 
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Figure 4.2. Northern blot verification and sequencing of PA-8P19 cDNA done. (A). 
Hybridization of PA-8P19 cDNA with RNA of A431 cells on nylon membrane by 
Northern blot analysis. The 18S and 28S rRNA confirmed the equal loading on each lane. 
(B). The cDNA plasmid was subjected to automatic sequencing by using Ml3 forward 
and reverse primers. The sequence was then submitted to the Genbank database by 
BLAST search. This clone was 347 b.p. (the underline region) which has no sequence 
homology to any regions of known gene. The letters in red at 5' end was the H-AP19 
primer sequence and that in blue at 3, end was the oligo-dT primer H-TnA used in 
differential display. Cell lines: P: A431/pareiit cells; A: A431/A10A cells; N: 
A431/CP500N cells 
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4.3.2. Gene expression profile of clone PA-8P19 in human tissues and 
other tumor cell lines. 
After Northern blot verification of clone PA-8P19 expression in A431 cells, the relative 
expression pattern in human tissues and other tumor cell lines were studied by 
hybridization of ^^P-dCTP radiolabeled cDNA probe with Multiple Choice Northern 
Blots from OriGene Technologies, Inc. and nylon membrane with RNA of different 
tumor cells respectively. The size of the gene indicated by Northern blot analysis was 
about 2.1kb. Expression of PA-8P19 was detected predominately in heart, but low in 
brain, lung and stomach (Figure 4.3A). Moreover, the expression of PA-8P19 was 
demonstrated in all human tumor cell lines as indicated in Northern blot analysis. The 
tumor cell lines in the membrane including 1) human breast carcinoma, MCF-7 cells 
(estrogen-dependent), MDA-468 cells (estrogen-independent) 2) human prostate cancer, 
PC3, DU145 cells (androgen insensitive) and LNCaP cells (androgen sensitive) 3) colon 
carcinoma, CaC02 cells (expresses human carcinoembryonic antigen and mutant p53) 4) 
osteosacroma, U2-0S and Saos-2 cells 5) cervical squamous carcinoma, A431 parent, 
AlOA, SiHa and HeLa cells 6) hepatocellular carcinoma HepG2 parent (carry wild type 
p53) and HepG2-R (doxorubicin-resistant subline ofHepG2). 
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From Northern blot analysis, it was indicated that the expression was most significant in 
colon carcinoma CaC02, while less detectable in breast carcinoma MDA-468, prostate 
carcinoma PC-3, squamous carcinoma A and HeLa cells (Figure 4.3B). The PA-8P19 
expression level was not only tissue-specific but also related to some of the sensitivity of 
tumor cells to anti-cancer drugs. For instance, the expression was downregulated in 
squamous carcinoma A431 DOX resistant subline, AlOA, and hepatocellular carcinoma 
HepG2 DOX subline, HepG2-R (Figure 4.3C). 
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Figure 43. Distribution of the expression of the novel PA-8P19 cDNA clone in 
human tissue and tumor cell lines. (A). Relative expression pattern of PA-8P19 clone 
was shown by hybridization of the PA=8P19 cDNA probe with the 124ane human tissue 
blot (Origene Technologies, Inc.). Each lane contained 2 / / g of polyA+ RNA of 12 
human major tissues normalized by the signal of human /5 -actin cDNA probe that done 
by the manufacturer. The expression of novel clone was highest in human heart tissue. 
(B). Human tumor cell line expression of PA-8P19 clone with respect to their drug 
resistance sublines (C) was shown by Northern blot analysis. Each lane loaded with 10// 
g of total RNA resolving in 1% agarose/7M formaldehyde denaturing gel and transferred 
to nylon membrane. Equal RNA loading was ensured by 18S and 28S rRNA. Cell lines 
indicated by the same color of letter have the same type of tissue origin. 
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4.3.3. Regulation of PA-8P19 expression by DNA damaging agents 
In search of the regulatory pathway for the clone PA-8P19, Northern blot analysis was 
performed in A431 cells after incubation with several DNA damaging drugs. Acute 
exposure of A431 cells with 5//g/ml DOX for Ih followed by incubation in drug free 
medium, the expression of PA-8P19 in A431 parent cells was slightly downregulated 
after incubation in drug free medium for up to 24 hr. While the downregulation was more 
significant in N cells. However, PA-8P19 was found to be upregulated in A cells during 
the 24h drug free incubation (Figure 4.4A). In the case of cisplatin, the expression ofPA-
8P19 was also decreased in both A431 parent and N cells when the cells were exposed to 
CP for Ih and then incubated in drug free condition for 24h. In the case of A cells, PA-
8P19 was however upregulated during the 24h drug free incubation (Figure 4.4B). 
Although the level of induction by DOX and CP was higher in the A cells, the level of 
expression of PA-8P19 in A431 parent cells remained to be greater than that of the DOX-
resistant A cells throughout the course of DOX and CP treatment. Besides, the clone PA-
8P19 was upregulated by other DNA damaging agent, gamma irradiation, in A431 parent 
and A, and indicated that the clone may be regulated in response to DNA damage. The 
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Figure 4�4. Effects of DOX, CP and gamma-radiation on the expression ofPA-8P19 
in A431 cells by Northern blot analysis. The cells were treated with (A) 5 [i g/ml DOX 
or (B) 511 g/ml CP for 1 hour, or (C) exposed to lOGy of gamma irradiation and then 
incubated with various time courses in drug-free medium and then lyzed for RNA 
extraction. 10/ /g of RNA was loaded in each lane and separated in 1% agarose/7M 
formaldehyde denaturing gel before transferred to nylon membrane. Equal loading was 
demonstrated by the 18S and 28S rRNA. The expression was shown by hybridization 
with A431 RNA on membrane and then visualized by autoradiography. 
DOX: doxorubicin; CP: cisplatin 
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4.4. DISCUSSION 
Differential display is employed to study the gene expression profiles between A431 
parent and drug resistant celis. One of the advantages of using the technique is the 
possible of investigating novel genes that cannot be identified by cDNA microarray. 
In the study, underexpression of the novel cDNA clone PA-8P19 in both DOX- and CP-
resistant, A and N, cells was chosen for fiirther investigation of its role in regulation of 
drug sensitivity in cells. The high expression of PA-8P19 in human heart tissue which 
may be important and involved in structural function in heart. Maintainence of high level 
in colon carcinoma may be important in tumorgenesis and cancer development. Also, 
DNA damaging agents such as DOX, CP and gamma irradiation induced PA-8P19 
expression in all A431 cells. For DOX and CP, the upregulation was most obvious and 
significant in A cells but lesser extent in N. While A431 parent was downregulated when 
incubated in DOX and CP for 1 hr and then up to 24hr in drug free treatment. Similarly, 
the clone PA-8P19 was upregulated by gamma irradiation implied PA-8P19 may be 
involved in DNA damaging regulatory pathway in cells. 
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For further characterizing for its role in drug resistance, cloning of full-length cDNA may 
be obtained by Rapid Amplification of 5’ and 3’ cDNA Ends (RACE) or screening of 
cDNA library in future. 
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CHAPTER FIVE 
Profiling and Identification of Differentially 




5.1.1. Protein analysis on a proteomic scale 
As the drug resistance mechanisms remain unclear and inconclusive, different strategies 
and technologies were exploited in search of novel or unknown underlying mechanisms 
that may lead to the chemoresistance in cancer. In the present study, the approaches of 
using RT-PCR based differential display and cDNA microarray for gene expression 
analysis had been discussed in the previous chapters. In order to extend the studies on the 
development of chemoresistance, another approach, as described in this Chapter, is to 
analyze global protein expression i.e., to phenotypically characterize cancer cell and their 
chemoresistant counterparts. Protein(s) related to drug resistance mechanisms were 
usually studied by conventional methods such as Western blotting. Such an approach is 
slow and inefficient for identification and characterization of relevant proteins and 
pathways. The development of two-dimensional gel electrophoresis (2-DE) and mass 
spectrometry (MS) allows the investigation of a large number of proteins simultaneously 
(Wilkins et al., 1996, Yan et al” 1996). The technologies of 2-DE and MS dominated a 
new field of protein science called proteomics. Currently, it is one of the popular 
applications in the area of cancer research (Wu et al, 2002). 2-DE is particularly powedlil 
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in comparing different states of proteome of a biological system, for example 
resistant/sensitive, positive trait/normal (Walsh et al., 1998). 
Proteomics, a term coined in 1994 by Mark Wilkins and colleagues at Macqarie 
University in Sydney, refers to the study of the proteome (Wilkins et al., 1996, Wilkins et 
al., 1996). Proteome is PROTeins expressed by the genOME of an organism (Wilkins et 
al., 1997). 2-DE is a key separation technique in proteome analysis due to its advantage 
of simultaneous separation of hundreds of proteins at a time, high resolution and 
reproducible and inter-laboratory comparisons. Moreover, with the human genome 
sequence now determined (Bradbury, 2000), the field of molecular medicine is moving 
beyond genomcis to proteomics. Therefore 2-DE is becoming a popular method of 
choice for searching of differentially expressed proteins in various systems. 
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5.1.2. Protein expression profiling for studying drug resistance by two-
dimensional gel electrophoresis 
Although the term "proteomics" was first formalized in 1996, the primary experimental 
tool to display the differentially expressed proteins, two-dimensional gel electrophoresis, 
was first introduced by P.H. OTarrell (O'Farrell, 1975) and J. Klose (Klose, 1975) in 
1975. In the original technique, the first-dimension separation was performed in carrier 
ampholyte {CA)-containing polyacrylamide gels cast in narrow tubes. Few years later, 
the 2-DE technique has been improved to generate 2-D maps that are superior in terms of 
resolution and reproducibility. This new 2-D technique, developed by A. Gorg and 
colleagues (Gorg et al., 1985, 1988), utilizes an improved first-dimension separation 
method that replaces the carrier ampholyte-generated pH gradients with immobilized pH 
gradients (IPG) and replaces the tube gels with gel strips supported by a plastic film 
backing. 
Proteomics has been applied to detect protein-based target for better treatment of cancer. 
Various studies have been conducted and novel targets for drug resistance were rapidly 
identified in different cancers by the proteomic approach. Sinha et al. (Sinha et al., 1999) 
reported on the promising application of proteomics in the rapid identification of novel 
127 
and known proteins in colorectal carcinoma HT-29 and fibrosacroma EPF86-079. Two 
novel proteins and Rho-GDP dissociation inhibitor were overexpressed in the 
mitoxantrone-resistant cell lines. It is suggested that it blocks the apoptotic signal 
pathway mediated by Ras and c-Jun kinase. A conceivable consequence of this inhibition 
may be the increased resistance against cellular and environmental stresses caused by 
cytotoxic drugs used in chemotherapy. Also, overexpression of translationally controlled 
tumor proteins was shown in resistant cells by comparing the 2-D protein profiles of 
human melanoma (MeWo) cells and their chemoresistant counterparts (Sinha et al., 
2000). The information from these studies helps understanding the development of drug 
resistance. 
Besides, the development of drug-resistant phenotype is due to either induction of gene 
expression or selection phenomena during chemotherapy. For instance, using differential 
display proteomic approach, the complex alterations in protein expression could be 
successfully monitored, i.e. by comparing the protein profiles of daunorubicin (DRC)-
sensitive versus daunombicin-resistant pancreatic carcinoma cells. More information 
could be obtained from alterations in the protein profile of tumor cells that have been 
cultured in the presence of different DRC concentrations to simulate the circumstances in 
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a solid tumor. The resulting 2-DE profiles should highlight only those proteins, whose 
expression is altered due to DRC exposure (Moller et al., 2002). 
Recently, proteomic characterization is also being applied to human hepatocellular 
carcinoma (HCC) cell lines (Seow et al.’ 2000, Yu et al., 2000), tissues (Kim et al., 2002) 
and normal liver in order to establish proteome maps. These results can be the basis for 
the construction of the differential proteome database and identification of tumor markers. 
In this Chapter, the proteomic comparison between human squamous A431 parent cells 
and its drug-resistant cells, AlOA and CP500N, were examined by using two-
dimensional gel electrophoresis. Differentially expressed proteins were identified using 
MALDI-TOF. 4 of the 13 proteins were overexpressed in drug resistant cells. Some of 
the proteins were confirmed by Western blotting. Further characterization is needed for 
the investigating of the role of these proteins in drug resistance of cells. The schematic 
drawing of 2-DE of A431 cells was shown in Figure 5.1. The protocol for 2-DE will be 
described in the following section. 
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5.2. MATERIALS AND METHODS 
5.2.1. Materials 
Chemicals Company 
• 3-[(3-cholamidopropyl)dimethyllammoninio] - USB 
propanesulfonate (CHAPS) 
• a-cyano-4-hydroxycinnamic acid Sigma 
• Acetic acid BDH Laboratory Suppliers 
• Acetonitrile Sigma 
• Ammonium biocarbonate Sigma 
• Aprotinin Sigma 
• BCA proteins assay Boehringer Mannheim 
• Benchmark Prestained protein marker Invitrogen Corp. 
• Bio-Rad Protein Assay Kit Bio-Rad 
• Copper II sulfate.5H2O Sigma 
• ECL Western blotting detection reagents Amersham Biosciencs 
• Ethanol BDH Laboratory Suppliers 
• Formaldehyde Sigma 
• Immobiline DryStrips pH 3-10 Amersham Biosciences 
• Leupetin Boehringer Mannheim 
• Mass spectrometric grade trypsin Promega 
• Methanol BDH Laboratory Suppliers 
• Polyoxyethylenesorvitan monolaurate 
(Tween 20) Sigma 
• Potassium ferricyanide Sigma 
• Sequazyme peptide standards kit Applied Bio systems 
• Silicone oil Amersham Biosciences 
• Siliver nitrate Sigma 
• Sodium thiosulfate pentahydrate Sigma 
• Thermersol Sigma 
• Thiourea Sigma 
• Trifluoroacetic acid Sigma 
• Triton X-100 Boehringer Mannheim 
• Urea Sigma 
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Antibodies Company 
• Anti-Protein kinase C epsilon Santa Cruz 
• Anti-minichromosome maintainence 5 Santa Cruz 
• Horseradish peroxidase conjugated secondary 
Antibody (rabbit, goat) Santa Cruz 
Instruments Company 
• 2D ImageMaster Software Amersham Biosciences 
• Amersham Pharmacia IPGphor Isoelectric 
focusing unit Amersham Biosciences 
• Data Explorer version 4.0 Applied Biosystems 
• Immobiline-P transfer membrane Millipore 
• MALDI stainless steel plate Applied Biosystem 
• Mini-Protean II electrophoresis apparatus Bio-Rad 
• Protean II xi electrophoresis apparatus Bio-Rad 
• SpeedVac vacuum drier Savant 
• Voyager-DE PRO MALDI-TOF mass spectrometer Applied Biosystems 
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5.2.2. Methods 
5.2.2.1. Cell culture and cell lines 
Human squamous carcinoma A431 cells, and its sublines were cultured in Dulbecco 
modified Eagle's medium supplemented with 10% fetal bovine serum and 5mM L-
glutamate in 37�C humidified 10% CO2 incubator. 
5.2.2.2. Two-dimensional gel electrophoresis 
I. Sample preparation 
A431/P (6X105), AlOA (8 XI0^) and CP500N (7 XIO^) cells were seeded in 100mm 
dishes for 2 days to reach the exponential phase. Then, the cells were harvested when a 
monolayer culture was attained. During harvesting, the cells were washed by lOmM Tris-
HCl buffer to remove the culture medium. The cells were then scraped off with a cell 
scraper in lysis buffer containing 8M urea, 40mM Tris and 4% CHAPS (3-[(3-
cholamidopropyl)-dimethyl-ammonio]-1 -propanesulfonate). The cell lysate was then 
centrifiiged at 14000 rpm for 30 min at 4°C. After centrifugation, the supernatant was 
collected and the protein content was measured by using Bradford assay (Bio-Rad, 
Hercules, CA, USA), aliquots containing 250 /zg of protein were lyophilized at -70°C 
until use. The protein was then analyzed by 2-DE. 
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II. First-dimensional gel: Isoelectric focusing (lEF) 
The first-dimensional lEF was performed on precast 13cm Immobiline Drystrips pH 3-10 
(Amersham Pharmacia Biotech) at 20�C with a maximum current setting of 50 // A/strip 
using an Amersham Pharmacia IPGphor lEF unit (Amersham Pharmica Biotech). The 
strips were rehydrated for a minimum of 16h in ceramic strip holders in 300 / /L of 
sample containing 7M urea, 2M thiourea, 4% CHAPS, 20mM dithiothreitol (DTT), 2% 
IPG buffer pH 3-10 and bromophenol blue. A low voltage of 30V was applied during 
rehydration. After rehydration, the proteins were focused succeedingly for 3h at 150V, 
2h at lOOOV, 2h at 2000V and then the focusing were continued at 4000V for 4h to give 
a total of 25000kVh on an IPGphor. After the first-dimensional lEF, IPG gel strips were 
placed in an equilibration buffer (6M urea, 2% SDS, 30% glycerol, 50mM Tris-HCl， 
pH8.8) containing 1% DTT for 15 min with shaking. The strips were replaced with fresh 
equilibration buffer for ftirther 15 min with shaking before placing them on a 10% 
polyacylamide gel. 
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III. Second dimensional gel: Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
Separation in second dimension was carried out using Protean II xi electrophoresis 
equipment (Bio-Rad) and Tris-glycine buffer (25mM Tris, 192mM glycine) containing 
1% SDS. The equilibrated gel strips were placed against one of the glass plates with 
agarose sealing to prevent it from moving in the electrophoresis buffer. SDS-PAGE was 
performed using a 10% polyacrylamide gel running at a current of 20mA per gel for 
initial Ih and then 60mA thereafter. Second-dimensional PAGE was developed until the 
bromophenol blue dye marker had reached the bottom of the gel. 
IV. Protein visualization and image analysis 
After the proteins were separated in polyacrylamide gel, the gels were visualized by 
silver staining. For silver staining, the gels were fixed in 50% methanol, 12% acetic acid 
and 0.05% v/v formalin (37% formaldehyde in water) for overnight, followed by 
washing with 50% ethanol for 20 min three times. Gels were pretreated for 1 min in a 
solution of 0.02% sodium thiosulfate (Na2S203). This was followed by three 1 min 
washes in deionized water. Proteins were stained in a solution containing 0.2% silver 
nitrate (AgNOs) and 0.075% v/v formalin for 1 h, and washed twice in deionized water 
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for 1 min. Subsequently, the gels were developed in a solution of 6% sodium carbonate 
(Na2C03), 0.08% v/v formalin and 0.0016% NaaSiOg. When the desired intensity was 
attained, the developer was discarded and stopped by 50% methanol, 12% acetic acid. 
Protein patterns in the gels were recorded using a high-resolution ImageScanner 
(Amersham Pharmacia Biotech.). Gel image matching was done with ImageMaster 2D 
Elite Software (Amersham Pharmacia Biotech.). Scanned gel images were processed to 
remove backgrounds, stainings on the gel borders and to automatically detect spots. 
V. In-gel digestion 
In-gel digestion of protein spots was performed before mass spectrometric analysis. After 
completion of staining, the spots of interest were excised with a bladzor and put into a 
1.5ml microtube. The proteins were soaked in the destaining solution containing 30mM 
potassium ferricyanide and lOOmM NaiSiOs for 10 min. After destaining, the proteins 
were washed with doubled distilled water for 15 min three times, and then with 50% 
acetonitrile (ACN) and 25mM ammonium bio carbonate, pH8.0 for 15 min three times. 
The solvent volumes were about twice the gel volume. Liquid was removed, 100% ACN 
was added to the gel particles for dehydration and the mixture was left for 5 min. The 
proteins were dried by SpeedVac vaccum drier (Savant) for 1 h. The proteins were 
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digested in cold 10/zg trypsin in 25mM ammonium biocarbonate for overnight at 37�C. 
After overnight digestion, the gel splice were soaked in 50% ACN/ 5% trifluoroacetic 
acid (TFA) for 60 min. The supernatant was recovered, and the extraction was repeated 
twice for further 60 min. The extracts were pooled and dried in the vacuum drier until 
completely dryness and stored at -80°C for fiirther analysis. 
VII. Matrix-assisted laser desorption ionization Time-of-Flight Mass spectrometry 
(MALDI-TOF-MS) and database search 
Tryptic peptide and the peptide calibrants in Sequazyme peptide standards kit were 
redissolved in matrix a-cyano-4-hydroxycinnamic acid (a-CHCA) separately. The 
mixture solution was then spotted on the MALDL stainless steel plate and dried. The 
dried samples and calibrants were analyzed in a Voyager-DE PRO MALDI-TOF mass 
spectrometer (PerSeptive Biosystems, Applied Bio systems). The proteins were identified 
by searching in SWISS-PROT databases using MS-FIT (Protein Prospector; UCSF, San 
Francisco, CA, USA) (http://prospector.ucsf.edu). All mass searches were performed 
using a mass window between 1000 and 10000 Da, and included human sequences. The 
criteria for positive identification of proteins were as follows: i) A mass tolerance of 200 
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PPm, ii) at least four matching peptide masses, and iii) molecular weight and pi of 
identified proteins should match estimated values obtained from image analysis. 
5.2.2.3. Western blot analysis 
The cells were lysed in Lammaeli's lysis buffer containing 1% Triton-X 100. The 
proteins were then resolved on SDS-polyacrylamide gel and blotted into Immobilion-P 
membranes. The membranes were blocked with 5% non-fat dry milk and incubated for 2 
hour with monoclonal antibodies MCM5 and PKCe. They were washed and incubated 
with corresponding secondary antibodies such as anti-rabbit or anti-goat which were 
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Figure 5.1. Schematic drawing of two-dimensional gel electrophoresis protocol. 
Total protein was extracted from exponentially growing A431 cells by urea-containing 
lysis buffer. Proteins in rehydration buffer were applied in the Iimnobiline Drystrips pH 
3-10 and allowed for rehydration. The proteins were focused succeedingly and separated 
according to their isoelectric point (First dimension) as described in methodology. The 
strips were equilibrated with SDS equilibration buffer before transferred to 10% SDS 
polyacrylamide gel. The proteins were separated according to their molecular weight 
(Second dimension). The expression patterns were visualized by silver staining. Protein 
spots that are differentially expressed were excised and digested by trypsin overnight (in-
gel digestion). The digested peptides were subjected to MALDI-TOF analysis. The 
expression patterns were verified by Western blot analysis. 
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5.3. RESULTS 
5.3.1. Identiflcation of differentially expressed proteins in A431 cells by 
two-dimensional gel electrophoresis 
In order to extend our studies on the development of drug resistance mechanism, protein 
expression profile of human squamous carcinoma A431 cells, the parent, the DOX-
resistant A and CP-resistant N sublines, were investigated by two-dimensional gel 
electrophoresis method. Protein was extracted by urea-containing lysis buffer and applied 
in the rehydrated immobilized pH gradient pH 3-10 strips. The protein was focused in 
stepwise condition as described in the methodology. After equilibration of strips into 
SDS-containing buffer, the protein in strips was separated by 10% SDS polyacrylamide 
gel and visualized by silver staining (Figure 5.2). Nineteen protein spots from the gel 
were identified to be differentially expressed among different A431 sublines and were 
excised for mass spectrometric analysis (Figure 5.3). Thirteen of them were successfully 
identified by peptide mass fingerprinting MALDI-TOF from Applied Biosystems and 
were summarized in Table 5.1. Five proteins were found to be upregulated only in A 
cells and four were downregulated in both A and N cells. The remaining four were only 
downregulated in N cells. The differential expression of thirteen protein spots between 
A431 parent and drug-resistant cells were shown in Figure 5.4. The resulting digested 
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peptide peaks were subjected to MS-FIT software and were identified by searching the 
SWISS-PROT database. After protein identification, two of them, MCM5 and PKC s, 
were verified by Western blot analysis to be differentially expressed and the pattern was 
consistent with the 2D analysis in A431 cells. The level of MCM5 was downregulated in 
both drug resistant cells as compared to the parent cells. In the case of PKC s, the 
expression was higher in A cells than that in the parent and N cells (Figure 5.5). 
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Figure 5.2. Protein profiling of human squamous carcinoma A431 cells by using 
two-dimensional gel electrophoresis. Protein was lysed in urea-containing buffer and 
300ug of protein lysate was focused in stepwise condition on a pH 3—10 IPG strips 
before separated by 10% SDS polyacrylamide gel. Protein maps were visualized and 
analyzed by silver staining and ImageMaster 2D software respectively. The differentially 
expressed proteins were excised and digested in trypsin for mass spectrometric 
identification. The one shown was the representative examples of at least four different 
gels from each cell line. 
Cell lines: P: A431/parent cells; A: A431/A10A cells; N: A431/CP500N cells 
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Figure 5.3. Protein spots with differential expression between A431 parent and drug 
resistant cells. The spots were indicated as circle in black color. Gels were analyzed by 
ImageMaster 2D computer software and protein spots that appeared to be down/up-
regulated were numbered. A total of 19 protein spots were identified. 
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Figure 5.4. The 13 differentially expressed protein spots identified by MALDL The 
differential expression between parent and drug-resistant, A and N, cells were shown 
after image analysis. 
p： A431/parent cells; A: A431/A10A cells; N: A431/CP500N cells 
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Protein Experimental Protein Protein ideiitification(a) 
spots MW / pi � expression level  
1 82286 / 8.6 P > A ~ N P33992 
H.S. DNA replication licensing factor  
MCM5 (CDC46 homolog)  
2 82268 / 9.0 P ~ A > N Q14123 
H.S. calcium-dependent cyclic nucleotide  
phosphodiesterase IC  
3 82433 / 6.8 P > A ~ N Q92499 
H.S. ATP-dependent helicase DDXl  
(DEAD-box protein 1) 
4 77051 /6.8 P > A > N P02787 
H.S. Serotransferrin precursor  
(Transferrin)  
5 77554 / 7.3 P > A > N 015254 
H.S. Acyl-coenzyme 
A oxidase 3，peroxisomal  
6 77564 / 7.8 A > P �N P24723  
H.S, Protein kinase C，epsilon type  
7 67639 / 5.6 A > P ~ N Q9H2C0 
H.S. Gigaxonin 
8 66695 / 5.7 A > P ~ N Q14005 ~ 
H.S. InterIeukin-16 precursor (IL-16)  
9 65758 /12 A > P > N Q15776  
H.S. Zinc finger protein 192 
10 46268 / 83 P �A>N P 29043 
H.S. 47kDa heat shock protein precursor 
f i 20132/ 5.3 A > P �N Q16548 
H.S. Bcl-2-related protein Al  
12 27077 / 5.8 P �A > N QY657 
H.S» Spindlin (Ovarian cancer-related  
protein)  
13 28870 / 6.6 P �A > N P00915 
H.S, Carbonic anhydrase I (CA-I) 
147 
Table 5.1. Summary of proteins identified to be differentially expressed in A431 
parent and drug resistant cells. From protein spots in the 2-D gel, the identity was 
searched against the SWISS-PROT database by MS-FIT search. Ninthteen protein spots 
in A431 parent cells were chosen, excised and destained. After destaining the gel, the 
protein spots in gels were digested by modified trypsin overnight. The digested protein 
was dried by SpeedVac vacuum drier before analysis. The proteins were resuspended in 
the a-CHCA matrix on MALDI plate and subjected to MALDI identification. 
(a) Protein identification was performed by peptide mass fingerprinting (MALDI-TOF). 
Overall, 13 of 19 protein spots have been identified. 
(b) Thoretical pi and MW. 
Cell lines: P: A431/parent cells; A: A431/A10A cells; N: A431/CP500N cells; H.S.: 
homo sapiens 
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Figure 5.5. Western blot verification of the expressions of two of the proteins 
identified by two-dimensional gel electrophoresis. The basal levels of MCM5 and 
PKC 8 in the A431 cells were determined by Western blot. Protein was extracted from 
exponentially growing ceils and resolved on SDS-PAGE and later immunoblotted with 
respective antibodies with 40|ig protein. Almost identical data were obtained from three 
independent experiments. 
Cell lines: P: A431/parent cells; A: A431/A10A cells; N: A431/CP500N cells 
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5.4. DISCUSSION 
5.4.1. Two-dimensional gel electrophoresis as a powerful tool for 
identiflcation of differential protein expression in A431 cells 
This study was aimed to identify and analyze differential protein expression among 
human squamous carcinoma A431 cells and its sublines, DOX-resistant A and CP-
resistant cells N cells�Identification of differentially expressed proteins would provide an 
alternative pathway in exploring drug resistance mechanisms in tumors. 
Among the nineteen protein spots found to be differentially expressed, thirteen of them 
were successfully identified by MALDI. The remaining was found to have no signals 
after laser injection to the digested protein spot from the MALDI. 
Among the thirteen protein spots identified by MALDI, all of them were known proteins. 
Five of them were upregulated in A cells but not in N cells. Four were downregulated in 
both A and N cells. The remaining four were found to be downregulated in N cells but 
not in A cells. The identified proteins play important role in various physiological 
pathways: i.e. proteins that involve in DNA replication (mini-chromosome maintainence 
5), RNA synthesis (ATP-dependent helicase Dead Box 1), tumorigenesis (protein kinase 
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C 8) and apoptosis (Bcl-2 related Al) in cancer. Furthermore, it was also found that the 
overexpression of PKC 8 in cisplatin-resistant ovarian carcinoma was associated with 
drug resistance (Basu et al., 1995). Further investigation was needed to understand the 
relationship between drug resistance mechanisms and the proteins identified. 
Two-dimensional gel electrophoresis is a powerful, high throughout and widely used 
method for the analysis of complex protein mixtures extracted from cells, tissues, or 
other biological samples. It takes the advantages that it can overcome the limitations in 
conventional techniques such as Western blotting. The 2-DE method has the potential to 
separate several thousand proteins in a single experiment and therefore provides the 
opportunity to detect differences in protein expression between two or more samples by 
comparative analysis of global protein patterns (Gorg et al, 1988, Klose et al., 1995, 
Goddlett et al, 2000, McDonald et aL, 2000). The protein expression pattern can be 
obtained in 3 days and allowed for visualizing of a large number of proteins. Moreover, 
only fetomolar or attomolar quantities of separated proteins are required for mass 
spectrometric analysis (Goddlett et al., 2000) Burlingame et al” 2000, Tomer, 2001). It is 
a very powerful, sensitive and rapid analytical measurement for identifying up to 
hundreds of proteins simultaneously. 
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Though two-dimensional gel electrophoresis is a powerful and efficient technique for 
identification of differentially expressed proteins, there are still several limitations. For 
instances, it is difficult to detect proteins on 2-D gels with molecular mass greater than 
100 000 Da and those with pi values less than 4 or higher than 9. Additionally, in 
proteomic studies, less-abundant proteins are sometimes not displayed in the gel (Gygi et 
al., 2000) and different proteins can co-migrate to the same spot due to proteins with 
similar MW or pi (Gygi et al., 2000 and Vuong et al , 2000). Also, proteins like 
membrane proteins and nuclear proteins are poorly water-soluble and hence they cannot 
easily extracted or migrated during 2-DE (Wu et al., 2002). Furthermore, a lot of 
antibodies and sufficient time are required in order to screen the proteome by Western 
blotting. 
To improve the performance of 2-DE, it is advisable to keep sample preparation as 
simple as possible for minimizing proteins loss or aggregation (Berkelman et al., 1998). 
For example, protein can be extracted with urea-containing buffer and/or followed by 
trichloroacetic acid/acetone precipitation. Moreover, enrichment or prefractionation 
strategies are needed to reach less abundant proteins and introduction of low current as 
performed in this study during rehydration of IPG strips prior to electrophoresis resulted 
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in improved resolution of very high molecular weight proteins (Gorg et al., 1999, Alaiya 
et al., 2000, Gorg et al., 2001). In addition, a high resolution separation can be achieved 
by using multiple overlapping, narrow IPG strips in the first dimension (ultrazoom-in-
gels) (Wildgruber et al., 2000, Moving et al., 2001) or by extending the separation 
distance, whilst a single wide pH gradient e.g. IPG 3-12 (Gorg et al., 2000) offers an 
overview of the state of the proteome� 
General practice and precautions should be taken before each step of two-dimensional 
gel electrophoresis and mass spectrometric analysis so as to minimize low resolution and 
increase the reproducibility of protein expressions. For instance, optimal focusing time 
must be provided and prolonged if the final voltage is not achieved during set ramping 
time (Berkeiman et al., 1998) so as to minimize the distortion of 2-D pattern and interfere 
the reproducibility. Also, developing time in silver staining between different gels should 
be consistent, otherwise, image variations affect the comparison of protein expression. 
Due to the high sensitivities of MS, careless sample handling or use of buffers and 
reagents that are not optimized for high sensitivity applications will inevitably lead to 
contamination with proteins (Goddlett DR et al., 2000). It is therefore important to avoid 
contamination by maintaining a clean work environment. 
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Other proteomic strategy has emerged such as multi-dimensional protein identification 
technology (MUDPIT) in 2001 (Wolters DA et al., 2001). Proteins are digested by one or 
more proteases and then the mixture is fractionated by strong cation exchanger column 
and reverse phase column coupled by MS analysis. Large number of proteins can be 
identified but cannot be accurately quantified, i.e. only determine whether they are 
present or absent. Besides, methods such as capillary isoelectric focusing (Shen Y et al., 
2000), capillary electrophoresis (Severs JC et al., 1996) coupled to MS have been 
developed. However, it is still impractical for identifying entire protein complement from 
a cell. Time is required to modify the protocol so as to identify and characterize 
differentially expressed proteins effectively. Currently, two-dimensional gel 
electrophoresis and mass spectrometry remains to be one of the most important high 




Conclusion and Perspectives 
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Drug resistance is one of the main problems encountered in cancer chemotherapy. 
Extensive publications and research revealed many underlying drug resistance 
mechanisms such as overexpression of Pgp, MRP and GST-pi in tumors. However, 
inconclusive results were also shown in different types of carcinoma and indicated that 
the resistance mechanisms are multifactorial. Therefore, further studies are needed in 
exploring the insensitivity of tumor cells to chemotherapeutic drugs. 
It was found that changes in gene expression or loss of its function were induced by long-
term incubation of chemotherapeutic drugs or during the process of drug selection in 
chemotherapy. Therefore, gene which alters its expression in chemotherapy may be a 
potential target for therapy and characterization of their role in drug sensitivity may help 
understanding the drug resistant pathways in cells. In order to monitor gene alteration in 
cancer cells, high throughput and powerful techniques are required to study the gene 
expression profile between parent and drug-resistant cells. Three types of technologies 
were used in the present study including two-dimensional gel electrophoresis (2-DE), 
cDNA microarray and differential display (DD) in exploring proteins or genes that are 
involved in drug resistance mechanisms in human squamous carcinoma A431 cells. Both 
DD and microarrays are conceptually simple. Microarrays visualize large sets of genes in 
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a high-throughput fashion. Once the signal is detected after hybridization, differentially 
expressed genes on each spot can be identified. However, the genes detected are only 
limited to the known genes in cells and time is required for confirmation of the 
expression patterns by RT-PCR, Northern blotting and Western blotting. While DD 
allows a simultaneous comparison of more than 2 samples of treatment, it is sequence-
dependent and capable of detecting both known and novel genes. Although DD is one of 
the major tools, high rate of false positives may occur. Besides, a new approach, 2-DE, 
was used to study the proteomes in drug-resistant cells. This allows separation of 
hundreds of proteins in a single gel and rapid identification can be obtained after protein 
digestion and subjected to MALDL But high molecular weight protein cannot be easily 
detected and different proteins will comigrate to the same spots in the gel. All these 
technologies are widely used in analyzing drug resistance mechanisms. Different 
approaches allow the identification of proteins or genes other than that are typically 
expressed drug resistant genes. 
It was found that one of the differentially expressed genes identified by DD, vacuolar 
proton pump subunit c, was associated with modulation of cisplatin sensitivity and CP-
induced apoptosis in A431 cells through alteration in cellular pHi. The results suggested 
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that cytosolic acidification enhanced CP-induced apoptosis and alkalinization in CP500N 
cells that overexpressed V-ATPase subunit c may protect cisplatin induced cell death and 
cytotoxicity. Besides，a novel gene was identified and its expression can be induced by 
incubation of cells with DNA damaging agents such as DOX, CP and radiation. To 
confirm its role in drug resistance, further characterization will need to be carried out, 
such as cDNA full-length cloning and antisense transfection assay. 
By using the 3 methods, cDNA microarray, DD and 2-DE, different types of genes were 
found to be differentially expressed between parent and drug resistant A431 cells. Some 
of these genes are known to be associated with drug resistance e.g. vacuolar proton pump, 
protein kinase c. Some are not e.g. aldehyde dehydrogenase, synaptopodin. Results from 
the study supported the idea that the drug resistance mechanisms are multifactorial. In the 
present study, one gene was characterized and allowed us to understand part of the 
underlying mechanisms of drug resistance in cells. In-depth investigation is needed in 
exploring drug resistance mechanisms so as to improve the drug efficacy or modulate 
drug sensitivity in cancer therapy. 
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